睿知中国医院研究地图
候选清单

郑州郑州大学

河南省人民医院

Henan Provincial People's Hospital

在本站收录的 61 种疾病中,这家医院列在其中 37 种下,依据是它牵头的研究论文,以及它作为牵头方或研究中心登记的试验。

这里展示的是公开记录中的研究活动,不是医疗水平评级。能否为某位患者提供帮助,应由医院和主治医生判断。

这家医院的官网还没有核对。

联系这家医院

河南省人民医院的研究

选择一种疾病,查看背后的论文和试验。 每个方块显示 2021–2025 年牵头的论文数和每年的数量。

只包括本站收录的 61 种疾病。未列出某种疾病,表示在这些记录中这家医院没有达到该病的列出标准,不代表它不诊治该病。 哪些医院会被列出

  1. 鼻咽癌Nasopharyngeal carcinoma3 篇牵头论文
  2. 食管鳞状细胞癌Oesophageal squamous cell carcinoma20 篇牵头论文
  3. 肝细胞癌Hepatocellular carcinoma30 篇牵头论文
  4. 胃癌Stomach cancer25 篇牵头论文
  5. 肺癌Lung cancer66 篇牵头论文
  6. 胰腺癌Pancreatic cancer13 篇牵头论文
  7. 乳腺癌Breast cancer39 篇牵头论文
  8. 胶质瘤Glioma56 篇牵头论文牵头 6 项开放试验
  9. 视网膜母细胞瘤Retinoblastoma2 篇牵头论文
  10. 脊索瘤Chordoma0 篇牵头论文
  11. 骨肉瘤Osteosarcoma7 篇牵头论文
  12. 胃肠道间质瘤Gastrointestinal stromal tumour0 篇牵头论文
  13. 神经母细胞瘤Neuroblastoma3 篇牵头论文
  14. 尤文肉瘤Ewing sarcoma0 篇牵头论文
  15. 多发性骨髓瘤Multiple myeloma5 篇牵头论文
  16. 淋巴瘤Lymphoma13 篇牵头论文
  17. 血友病 AHaemophilia A2 篇牵头论文
  18. 血栓性血小板减少性紫癜Thrombotic thrombocytopenic purpura1 篇牵头论文
  19. 范可尼贫血Fanconi anaemia1 篇牵头论文
  20. 视神经脊髓炎谱系疾病Neuromyelitis optica spectrum disorder2 篇牵头论文
  21. 重症肌无力Myasthenia gravis2 篇牵头论文
  22. 烟雾病Moyamoya disease5 篇牵头论文
  23. 冠心病Coronary heart disease26 篇牵头论文
  24. 先天性心脏病Congenital heart disease14 篇牵头论文
  25. 脊柱侧弯Scoliosis0 篇牵头论文
  26. 抗 NMDA 受体脑炎Anti-NMDA receptor encephalitis2 篇牵头论文
  27. 大动脉炎Takayasu arteritis0 篇牵头论文
  28. 特发性肺纤维化Idiopathic pulmonary fibrosis5 篇牵头论文
  29. 肌萎缩侧索硬化症Amyotrophic lateral sclerosis1 篇牵头论文
  30. 杜氏肌营养不良Duchenne muscular dystrophy1 篇牵头论文
  31. IgA 肾病IgA nephropathy1 篇牵头论文
  32. 成骨不全症Osteogenesis imperfecta0 篇牵头论文
  33. 原发性胆汁性胆管炎Primary biliary cholangitis0 篇牵头论文
  34. 原发性硬化性胆管炎Primary sclerosing cholangitis0 篇牵头论文
  35. 遗传性大疱性表皮松解症Inherited epidermolysis bullosa2 篇牵头论文
  36. 遗传性血管性水肿Hereditary angioedema0 篇牵头论文
  37. Leber 遗传性视神经病变Leber hereditary optic neuropathy3 篇牵头论文

未列出的收录疾病:肝母细胞瘤、B 细胞急性淋巴细胞白血病、再生障碍性贫血、噬血细胞性淋巴组织细胞增生症、β 地中海贫血、非典型溶血性尿毒症综合征、IgG4相关性疾病、肝豆状核变性、胆道闭锁、肝包虫病、肺淋巴管平滑肌瘤病、脊髓性肌萎缩症、法布雷病、庞贝病、白塞病、Alport 综合征、戈谢病、尼曼-匹克病 C 型、先天性膈疝、先天性巨结肠、家族性腺瘤性息肉病、Majeed 综合征、NGLY1 缺乏症、ISG15 缺乏症。

癌症

鼻咽癌

Nasopharyngeal carcinoma

2021–2025 年中国大陆作者发表的 2,375 篇鼻咽癌 PubMed 英文论文中,这家医院牵头了 3 篇,占 0.1%。

牵头论文
3
2021–2025 年
牵头试验
1
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 1120232024: 0020242025: 112025

郑州有 4 家医院列在鼻咽癌下全国有 183 家医院列在鼻咽癌下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的鼻咽癌开放试验。

这些数字背后的记录
研究主题免疫治疗EB病毒与筛查
论文中的科室耳鼻喉/头颈外科肿瘤内科
牵头的论文3
  1. miR-34c-3p Inhibits Nasopharyngeal Carcinoma Development via Inhibiting M2 Polarization of Macrophages.2025Biomedical and environmental sciences : BES
  2. Biomarkers predicting clinical outcomes in nasopharyngeal cancer patients receiving immune checkpoint inhibitors: A systematic review and meta-analysis.2023Frontiers in immunology免费全文
  3. Hsa_circ_0000345 inhibits cell proliferation, migration and invasion of nasopharyngeal carcinoma cells via miR-513a-3p/PTEN axis.2022The journal of physiological sciences : JPS免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. Intermittent Oro-esophageal Tube Feeding in Late Dysphagia for Nasopharyngeal Carcinoma已撤回NCT06248879牵头方不分期2024-02 启动
PubMed 以外找到的论文(未计入)10
  1. Additional file 1 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop2022Figshare数据集
  2. Additional file 2 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop2022Figshare数据集
  3. Additional file 3 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop2022Figshare数据集
  4. Additional file 4 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop2022Figshare数据集
  5. Additional file 5 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop2022Figshare数据集
  6. Additional file 6 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop2022Figshare数据集
  7. Additional file 7 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop2022Figshare数据集
  8. Additional file 8 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop2022Figshare数据集
  9. Additional file 9 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop2022Figshare数据集
  10. Long intergenic non-protein coding RNA 02570 promotes nasopharyngeal carcinoma progression by adsorbing microRNA miR-4649-3p thereby upregulating both sterol regulatory element binding protein 1, and fatty acid synthase2021Figshare数据集

打开 PubMed 检索ClinicalTrials.gov

癌症

食管鳞状细胞癌

Oesophageal squamous cell carcinoma

2021–2025 年中国大陆作者发表的 2,923 篇食管鳞状细胞癌 PubMed 英文论文中,这家医院牵头了 20 篇,占 0.7%。

牵头论文
20
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 3320212022: 3320222023: 4420232024: 5520242025: 442025

郑州有 6 家医院列在食管鳞状细胞癌下全国有 192 家医院列在食管鳞状细胞癌下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Value of Pleural Lavage Cytology in Resectable Esophageal Carcinoma Eastern Cooperative Thoracic Oncology Projects 2005, ECTOP-2005)
    分期
    未注明
    开始
    2022-07
    发布
    登记号
    NCT05443841

    年龄未注明(登记的条件)

    牵头:复旦大学附属肿瘤医院;另有 8 家列出的医院为研究中心上海、南通、合肥、天津、泰州、石家庄、西安、郑州

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题分子标志物与基因免疫治疗早期发现与内镜
论文中的科室肿瘤内科病理/检验科

这些论文过半是实验室或动物研究。

牵头的论文20
  1. Biocompatible hydrogel co-delivering salvigenin and iridium (III) complex overcomes cancer stemness and cisplatin resistance in esophageal squamous cell carcinoma.2026Colloids and surfaces. B, Biointerfaces
  2. Multi-omics analysis unveils a four-gene prognostic signature in esophageal squamous carcinoma and the therapeutic potential of PKP1.2025BMC cancer免费全文
  3. Perioperative the BTLA inhibitor (tifcemalimab) combined with toripalimab and chemotherapy for resectable locally advanced thoracic esophageal squamous cell carcinoma trial (BT-NICE trial): a prospective, single-arm, exploratory study.2025Frontiers in immunology免费全文
  4. METTL3-Mediated m6A Methylation Stabilizes IFI27 to Drive Esophageal Squamous Cell Carcinoma Progression Through an IGF2BP2-Dependent Mechanism.2025Journal of biochemical and molecular toxicology
  5. Screening, Validation, and Machine Learning-Based Evaluation of Serum Protein Biomarkers for Esophageal Squamous Cell Carcinoma Based on Single-Cell Subtype-Specific Genes.2025Journal of proteome research
  6. Case report of radiotherapy combined with anlotinib and immunotherapy for a patient with esophageal cancer and esophageal fistula.2024Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine
  7. Arntl-induced upregulation of DUSP1 inhibits tumor progression in esophageal squamous cell carcinoma by inactivating ERK signaling.2024Cancer biology & therapy免费全文
  8. DNMT1-driven methylation of RORA facilitates esophageal squamous cell carcinoma progression under hypoxia through SLC2A3.2024Journal of translational medicine免费全文
  9. EVA1B facilitates esophageal squamous carcinoma progression and recruitment of immunosuppressive myeloid-derived suppressor cells in the tumor microenvironment.2024Pharmacological research
  10. The anti-tumor activity of tangeretin in esophageal squamous cell carcinoma by inhibiting GLI2-mediated transcription of GPNMB.2024PloS one免费全文
  11. LincRNA-P21 knockdown facilitates esophageal squamous cell carcinoma cell progression by upregulating cadherin 5 via YTH domain containing 1.2023Acta biochimica et biophysica Sinica免费全文
  12. Exosomal circ_0026611 contributes to lymphangiogenesis by reducing PROX1 acetylation and ubiquitination in human lymphatic endothelial cells (HLECs).2023Cellular & molecular biology letters免费全文
  13. Hsa_circ_0046534 accelerates esophageal squamous cell carcinoma proliferation and metastasis via regulating MMP2 expression by sponging miR-339-5p.2023Cellular signalling
  14. The efficacy and safety of sintilimab combined with chemotherapy as the first-line treatment for metastatic esophageal squamous cell carcinoma.2023Medicine免费全文
  15. DNA methyltransferase 3 beta regulates promoter methylation of microRNA-149 to augment esophageal squamous cell carcinoma development through the ring finger protein 2/Wnt/β-catenin axis.2022Bioengineered免费全文
  16. HA-ADT suppresses esophageal squamous cell carcinoma progression via apoptosis promotion and autophagy inhibition.2022Experimental cell research
  17. Identification of a novel circ_0001946/miR-1290/SOX6 ceRNA network in esophageal squamous cell cancer.2022Thoracic cancer免费全文
  18. Fusobacterium nucleatum predicts a high risk of metastasis for esophageal squamous cell carcinoma.2021BMC microbiology免费全文
  19. RELT promotes the growth of esophageal squamous cell carcinoma by activating the NF-κB pathway.2021Cell cycle (Georgetown, Tex.)免费全文
  20. TMEM161B-AS1 suppresses proliferation, invasion and glycolysis by targeting miR-23a-3p/HIF1AN signal axis in oesophageal squamous cell carcinoma.2021Journal of cellular and molecular medicine免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)3
  1. Value of Pleural Lavage Cytology in Resectable Esophageal Carcinoma Eastern Cooperative Thoracic Oncology Projects 2005, ECTOP-2005)正在招募NCT05443841研究中心2022-07 启动
  2. TQB2450 Solution for Injection (TQB2450)+Paclitaxel+Cisplatin ± Anlotinib in the Treatment of Esophageal Cancer.状态不明NCT05013697研究中心II期2021-09 启动
  3. A Study of CS1001 in Subjects With Esophageal Squamous Cell Carcinoma已完成NCT04187352研究中心III期2019-12 启动
PubMed 以外找到的论文(未计入)9
  1. 2119P Perioperative study of BTLA combined with PD-1 and chemotherapy as bispecific immunosuppressants for resectable thoracic esophageal squamous cell carcinoma (BT-NICE trial): A prospective, single group, phase II study2025Annals of Oncology论文
  2. Additional file 2 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma2023Figshare数据集
  3. Additional file 3 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma2023Figshare数据集
  4. Additional file 4 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma2023Figshare数据集
  5. Additional file 5 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma2023Figshare数据集
  6. Encouraging efficacy of sintilimab combined with nanoparticle albumin-bound paclitaxel and platinum as the first-line treatment for metastatic esophageal squamous cell carcinoma: A retrospective study.2022Journal of Clinical Oncology会议摘要
  7. Preliminary study on the role and mechanism of KIRREL3 in the development of esophageal squamous cell carcinoma (ESCC)2022Research Square预印本
  8. LRP16 Promotes Proliferation and Migration of Esophageal Squamous Cell Carcinoma by Regulating Hippo Signaling Pathway2021Research Square预印本
  9. LncRNA HCP5 promotes malignant cell behaviors in esophageal squamous cell carcinoma via the PI3K/AKT/mTOR signaling2021Figshare数据集

打开 PubMed 检索ClinicalTrials.gov

癌症

肝细胞癌

Hepatocellular carcinoma

2021–2025 年中国大陆作者发表的 14,765 篇肝细胞癌 PubMed 英文论文中,这家医院牵头了 30 篇,占 0.2%。

牵头论文
30
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 7720212022: 7720222023: 2220232024: 3320242025: 10102025

郑州有 3 家医院列在肝细胞癌下全国有 194 家医院列在肝细胞癌下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Computer-Aided Diagnosis for Hepatocellular Carcinoma Microvascular Invasion
    分期
    未注明
    开始
    2025-09
    发布
    登记号
    NCT07170345

    年龄 18 岁 至 18 岁(登记的条件)

    牵头方不是列出的医院;另有 13 家列出的医院为研究中心上海、北京、南宁、广州、成都、沈阳、温州、珠海、福州、郑州

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题复发与预后影像、人工智能与早期发现乙肝与肝硬化
论文中的科室普外/肝胆胰外科影像/核医学科消化/肝病科肿瘤内科

这些论文过半是实验室或动物研究。

牵头的论文30
  1. WTAP contributes to the malignancy and stemness of hepatocellular carcinoma through upregulating N6-methyladenosine modification of ITGB4.2026Pathology, research and practice
  2. Value of Abbreviated Magnetic Resonance Sequence in Hepatocellular Carcinoma Screening: A Systematic Review and Meta-analysis.2025Academic radiology
  3. HLA-DR⁺ Tumor Cells Show an Association with a Distinct Immune Microenvironment and CD8⁺ T-Cell Exhaustion in HBV-Associated Hepatocellular Carcinoma.2025Advanced science (Weinheim, Baden-Wurttemberg, Germany)免费全文
  4. Imaging-Based Prediction of Ki-67 Expression in Hepatocellular Carcinoma: A Retrospective Study.2025Cancer medicine免费全文
  5. Multi-omics spatial characteristics of CD8+TRM cells in hepatocellular carcinoma and immunotherapy response prediction.2025Frontiers in immunology免费全文
  6. The safety and effectiveness of sintilimab versus camrelizumab, both plus targeted drugs, in advanced hepatocellular carcinoma.2025Frontiers in immunology免费全文
  7. Integrated bioinformatics and in vitro validation reveal TUBB as a core gene and therapeutic target in NAFLD-related hepatocellular carcinoma.2025International journal of biological macromolecules
  8. Increased expression of DNAJC7 promotes the progression of hepatocellular carcinoma by influencing the cell cycle and immune microenvironment.2025Journal of cancer research and clinical oncology免费全文
  9. FAIM modulates HCC progression via enhancing HMGA1 interaction with CDK7 and promoting its phosphorylation level.2025Journal of translational medicine免费全文
  10. Transcriptional regulation of tumor suppressor gene RASSF1A by HBx.2025Molecular and cellular probes
  11. OTUD7B is a new deubiquitinase targeting p53.2025Theranostics免费全文
  12. Proteo-genomic characterization of cirrhosis-associated liver cancers reveals potential subtypes and therapeutic targets.2024Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  13. Myocardial and Cerebral Infarction after Transarterial Bland Microsphere Embolization for Hepatocellular Carcinoma: A Case Report.2024Journal of vascular and interventional radiology : JVIR
  14. TDF and TAF inhibit liver cancer cell migration, invasion via p7TP3.2024Scientific reports免费全文
  15. LncRNA RP11-620J15.3 promotes HCC cell proliferation and metastasis by targeting miR-326/GPI to enhance glycolysis.2023Biology direct免费全文
  16. Noninvasive Prediction of Ki-67 Expression in Hepatocellular Carcinoma Using Machine Learning-Based Ultrasomics: A Multicenter Study.2023Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine
  17. Long non-coding RNA HAGLROS facilitates tumorigenesis and progression in hepatocellular carcinoma by sponging miR-26b-5p to up-regulate karyopherin α2 (KPNA2) and inactivate p53 signaling.2022Bioengineered免费全文
  18. LINC01419 Promotes the Proliferation of Hepatoma Cells by Recruiting XRCC5 and Regulating Its Phosphorylation to Repair DNA Damage.2022Disease markers免费全文
  19. Hydroxyacid Oxidase 2 (HAO2) Inhibits the Tumorigenicity of Hepatocellular Carcinoma and Is Negatively Regulated by miR-615-5p.2022Journal of immunology research免费全文
  20. LncRNA MAPKAPK5_AS1 facilitates cell proliferation in hepatitis B virus -related hepatocellular carcinoma.2022Laboratory investigation; a journal of technical methods and pathology
  21. The long non-coding RNA LIMT inhibits metastasis of hepatocellular carcinoma and is suppressed by EGF signaling.2022Molecular biology reports免费全文
  22. Sarcopenia as an Independent Risk Factor for Specific Cancers: A Propensity Score-Matched Asian Population-Based Cohort Study.2022Nutrients免费全文
  23. Deciphering the molecular mechanism of tetrandrine in inhibiting hepatocellular carcinoma and increasing sorafenib sensitivity by combining network pharmacology and experimental evaluation.2022Pharmaceutical biology免费全文
  24. Evaluation of Glypican-3 Expression in Hepatocellular Carcinoma by Using IDEAL IQ Magnetic Resonance Imaging.2021Academic radiology
  25. miR-199a-5p inhibits the proliferation of hepatocellular carcinoma cells by regulating CDC25A to induce cell cycle arrest.2021Biochemical and biophysical research communications
  26. Immune-associated molecular occurrence and prognosis predictor of hepatocellular carcinoma: an integrated analysis of GEO datasets.2021Bioengineered免费全文
  27. Development of an AI system for accurately diagnose hepatocellular carcinoma from computed tomography imaging data.2021British journal of cancer免费全文
  28. ZSCAN16-AS1 expedites hepatocellular carcinoma progression via modulating the miR-181c-5p/SPAG9 axis to activate the JNK pathway.2021Cell cycle (Georgetown, Tex.)免费全文
  29. Hybrid network with difference degree and attention mechanism combined with radiomics (H-DARnet) for MVI prediction in HCC.2021Magnetic resonance imaging
  30. CircRNA GFRA1 promotes hepatocellular carcinoma progression by modulating the miR-498/NAP1L3 axis.2021Scientific reports免费全文
中文论文(未计入)2
  1. [Circ_0026134 regulates the miR-1270/GRB2 pathway to affect the radiosensitivity of hepatoma cells].2024Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology免费全文
  2. [Problems and pitfalls of the hepatocyte-specific contrast agent gadoxetate disodium for assessing the main criteria of LI-RADS version 2018].2023Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)4
  1. Computer-Aided Diagnosis for Hepatocellular Carcinoma Microvascular Invasion正在招募NCT07170345研究中心2025-09 启动
  2. A Real-world Study of the Short-term Efficacy and Safety of E-TACE in Patients With Hepatocellular Carcinoma (HCC)状态不明NCT06023147研究中心不分期2023-09 启动
  3. Nurse-led Decision Counseling on Hepatocellular Carcinoma Screening已完成NCT04659005研究中心不分期2021-02 启动
  4. Autologous CAR-T/TCR-T Cell Immunotherapy for Solid Malignancies状态不明NCT03941626研究中心I/II期2019-09 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

胃癌

Stomach cancer

2021–2025 年中国大陆作者发表的 9,782 篇胃癌 PubMed 英文论文中,这家医院牵头了 25 篇,占 0.3%。

牵头论文
25
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 7720212022: 8820222023: 1120232024: 6620242025: 332025

郑州有 4 家医院列在胃癌下全国有 211 家医院列在胃癌下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的胃癌开放试验。

这些数字背后的记录
研究主题早期发现与内镜腹膜转移与晚期影像与人工智能
论文中的科室消化/肝病科病理/检验科肿瘤内科
牵头的论文25
  1. Spatial transcriptomic characteristics of gastric cancer in young and the expression and role of TMEM176B in gastric cancer cells.2025European journal of medical research免费全文
  2. Global Prevalence of Helicobacter pylori Infection-Associated Gastric Preneoplastic Lesions in Pediatric Patients: A Systematic Review and Meta-Analysis.2025Helicobacter
  3. An interpretable hybrid deep learning framework for gastric cancer diagnosis using histopathological imaging.2025Scientific reports免费全文
  4. The three-stage and seven-step method for laparoscopic radical gastrectomy: A new surgical procedure for gastric cancer.2024Asian journal of surgery
  5. Pathological complete remission (PCR) in a patient with unresectable gastric cancer undergoing preoperative conversion therapy.2024Asian journal of surgery
  6. Family-based Helicobacter pylori infection control and management strategy and screen-and-treat strategy are highly cost-effective in preventing multiple upper gastrointestinal diseases in Chinese population at national level.2024Helicobacter
  7. Benzimidazole-based structure optimization to discover novel anti-gastric cancer agents targeting ROS/MAPK pathway.2024Journal of biochemical and molecular toxicology
  8. Sensitivity and specificity of folate receptor α-positive circulating tumour cells in gastric cancer.2024Postgraduate medical journal
  9. Comprehensive analysis of risk factors associated with submucosal invasion in patients with early-stage gastric cancer.2024World journal of gastroenterology免费全文
  10. Relationship between the number of dissected lymph node and the pathological staging in esophagogastric junction adenocarcinoma.2023Asian journal of surgery
  11. Identification of a seven-cell cycle signature predicting overall survival for gastric cancer.2022Aging免费全文
  12. Feasibility and Tolerance of Apatinib plus PD-1 Inhibitors for Previously Treated Advanced Gastric Cancer: A Real-World Exploratory Study.2022Disease markers免费全文
  13. Non-invasive measurement of tumor immune microenvironment and prediction of survival and chemotherapeutic benefits from 18F fluorodeoxyglucose PET/CT images in gastric cancer.2022Frontiers in immunology免费全文
  14. Both family-based Helicobacter pylori infection control and management strategy and screen-and-treat strategy are cost-effective for gastric cancer prevention.2022Helicobacter
  15. "Two-Side Approach, Four-Step Dissociation" Surgical Technique for Splenic Hilar Lymphadenectomy During Laparoscopic Total Gastrectomy for Advanced Gastric Cancer.2022Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  16. Plasma Exosomal hsa_circ_0015286 as a Potential Diagnostic and Prognostic Biomarker for Gastric Cancer.2022Pathology oncology research : POR免费全文
  17. Family-based Helicobacter pylori infection status and transmission pattern in central China, and its clinical implications for related disease prevention.2022World journal of gastroenterology免费全文
  18. Gastric mucosal precancerous lesions in Helicobacter pylori-infected pediatric patients in central China: A single-center, retrospective investigation.2022World journal of gastroenterology免费全文
  19. Knockdown of hsa_circ_0091994 constrains gastric cancer progression by suppressing the miR-324-5p/HMGA1 axis.2021Aging免费全文
  20. A novel circular RNA circ_HN1/miR-628-5p/Ecto-5'-nucleotidase competing endogenous RNA network regulates gastric cancer development.2021Bioengineered免费全文
  21. Tissue-based metabolomics reveals metabolic signatures and major metabolic pathways of gastric cancer with help of transcriptomic data from TCGA.2021Bioscience reports免费全文
  22. CDC42EP3 is a key promoter involved in the development and progression of gastric cancer.2021Carcinogenesis
  23. m6 A transferase KIAA1429-stabilized LINC00958 accelerates gastric cancer aerobic glycolysis through targeting GLUT1.2021IUBMB life
  24. Arborinine, a potential LSD1 inhibitor, inhibits epithelial-mesenchymal transition of SGC-7901 cells and adriamycin-resistant gastric cancer SGC-7901/ADR cells.2021Investigational new drugs
  25. STROBE-clinical characteristics and prognosis factors of gastric cancer in young patients aged ≤30 years.2021Medicine免费全文
中文论文(未计入)1
  1. [Application of 3D-CT simulation image in the description of gastric artery variation to guide laparoscopic total gastrectomy].2021Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
它在 ClinicalTrials.gov 上的全部试验(任何状态)6
  1. HFNO Reduces Hypoxia During Sedated Gastroscopy or Colonoscopy in High Risk Patients状态不明NCT05510388研究中心不分期2022-09 启动
  2. Nasal Mask Kit in Gastrointestinal Endoscopy已完成NCT05405530研究中心不分期2022-09 启动
  3. Capnographic Monitoring in Gastrointestinal Endoscopy for Elderly Patients已完成NCT05030870研究中心不分期2021-09 启动
  4. HX008 Plus Irinotecan Versus Placebo Plus Irinotecan as Second-line Treatment in Advanced Gastric Cancer状态不明NCT04486651研究中心III期2020-09 启动
  5. Autologous CAR-T/TCR-T Cell Immunotherapy for Solid Malignancies状态不明NCT03941626研究中心I/II期2019-09 启动
  6. A Non-Interventional Study of Treatment Pattern and Clinical Outcomes in Chinese Participants With Gastric Cancer已完成NCT01839500研究中心2013-04 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

肺癌

Lung cancer

2021–2025 年中国大陆作者发表的 23,356 篇肺癌 PubMed 英文论文中,这家医院牵头了 66 篇,占 0.3%。

牵头论文
66
2021–2025 年
牵头试验
2
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
9
由其他机构牵头
每年牵头的论文数
2021: 101020212022: 9920222023: 101020232024: 171720242025: 19192025

郑州有 3 家医院列在肺癌下全国有 251 家医院列在肺癌下

这家医院参与的开放试验 9

依据 ClinicalTrials.gov 在 2026年11月18日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    RC148 Plus Platinum-Based Chemotherapy vs Tislelizumab Plus Platinum-Based Chemotherapy for First-Line Squamous Non-Small Cell Lung Cancer (sqNSCLC)
    分期
    III期
    开始
    2026-04
    发布
    登记号
    NCT07416474

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 66 家列出的医院为研究中心上海、临沂、乌鲁木齐、兰州、北京、南京、南宁、南昌、厦门、台州、合肥、哈尔滨、天津、太原、安阳、广州、徐州、成都、新乡、昆明、杭州、桂林、武汉、江门、沈阳、洛阳、济南、深圳、温州、烟台、珠海、石家庄、福州、苏州、襄阳、郑州、重庆、银川、长春、长沙、青岛

  2. 正在招募
    A Phase II Trial of LM103 for Adjuvant Treatment in Patients With Non-small Cell Lung Cancer
    分期
    II期
    开始
    2026-02
    发布
    登记号
    NCT07444437

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 3 家列出的医院为研究中心广州、郑州

  3. 正在招募
    Pragmatic AI-Assisted Lung Cancer Translational Study
    分期
    不分期
    开始
    2026-08
    发布
    登记号
    NCT07941128

    年龄 18 岁 至 未注明(登记的条件)

    牵头:浙江大学医学院附属邵逸夫医院;另有 1 家列出的医院为研究中心杭州、郑州

  4. 正在招募
    A Study Comparing TAK-928 With Docetaxel in Adults With Non-Small Cell Lung Cancer
    分期
    III期
    开始
    2025-11
    发布
    登记号
    NCT07217301

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 35 家列出的医院为研究中心上海、北京、南京、南昌、合肥、哈尔滨、天津、广州、徐州、成都、新乡、昆明、杭州、沈阳、泸州、济南、温州、石家庄、福州、西安、郑州、重庆、长沙

  5. 正在招募
    D-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standard Therapy Failure
    分期
    III期
    开始
    2024-03
    发布
    登记号
    NCT06300177

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 63 家列出的医院为研究中心上海、乌鲁木齐、兰州、北京、南京、南宁、南昌、南通、厦门、合肥、哈尔滨、天津、太原、安阳、常州、广州、徐州、成都、新乡、无锡、昆明、杭州、桂林、武汉、沈阳、洛阳、济南、海口、温州、湛江、潍坊、石家庄、福州、西安、遵义、郑州、重庆、长春、长沙

  6. 正在招募
    Transthoracic vs Transbronchial Cryoablation for Early-stage Peripheral Lung Cancer
    分期
    不分期
    开始
    2024-09
    发布
    登记号
    NCT06572540

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 5 家列出的医院为研究中心上海、广州、成都、杭州、郑州

  7. 正在招募
    A Dose-escalation and Dose-expansion Phase I/Phase II Clinical Study of Dositinib Mesylate Tablets (90-1408) in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer With Positive EGFR Mutation
    分期
    I/II期
    开始
    2022-10
    发布
    登记号
    NCT07231068

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 5 家列出的医院为研究中心北京、广州、郑州

  8. 正在招募
    Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors
    分期
    I/II期
    开始
    2021-09
    发布
    登记号
    NCT04930432

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 56 家列出的医院为研究中心上海、兰州、北京、南京、南宁、南昌、南通、厦门、台州、合肥、哈尔滨、大连、天津、太原、广州、徐州、成都、昆明、杭州、武汉、汕头、沈阳、济南、深圳、温州、潍坊、烟台、石家庄、福州、苏州、蚌埠、西安、郑州、重庆、长春、长沙、青岛

  9. 即将招募
    Novel Thin Bronchoscope Versus Ultrathin Bronchoscope for the Diagnosis of Peripheral Pulmonary Nodules
    分期
    不分期
    开始
    2025-09
    发布
    登记号
    NCT07135297

    年龄 18 岁 至 未注明(登记的条件)

    牵头:上海市胸科医院;另有 4 家列出的医院为研究中心上海、北京、南京、宁波、郑州

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
论文中的科室影像/核医学科肿瘤内科病理/检验科神经内科
牵头的论文66
  1. FBXL6 drives tumorigenesis in lung adenocarcinoma through ubiquitination and proteasomal degradation of CDKN1C.2026Experimental cell research
  2. Targeting NAD + biosynthesis suppresses TGF-β1/Smads/RAB26 axis and potentiates cisplatin cytotoxicity in non-small cell lung cancer brain metastasis.2025Acta neuropathologica communications免费全文
  3. Prognostic performance of the nutritional risk screening 2002 and the global leadership initiative on malnutrition in patients with lung cancer treated with immune checkpoint inhibitors.2025BMC cancer免费全文
  4. Metabolic and multi-model intravoxel incoherent motion parameters based 18F-FDG PET/MRI for predicting subtypes of inoperable non-small cell lung cancer.2025BMC cancer免费全文
  5. Identification of a Risk Signature and Immune Cell Infiltration Based on Extracellular Matrix-Related lncRNAs in Lung Adenocarcinoma.2025Critical reviews in eukaryotic gene expression
  6. Effect of Nebulized Dexmedetomidine on Postoperative Nausea and Vomiting in Female Patients Undergoing Radical Thoracoscopic Lung Cancer Resection: A Single-Center Randomized Controlled Trial.2025Drug design, development and therapyRCT免费全文
  7. Influence of diabetes mellitus on metabolic networks in lung cancer patients: an analysis using dynamic total-body PET/CT imaging.2025European journal of nuclear medicine and molecular imaging
  8. Targeting BUB1B-driven cancer stemness in lung adenocarcinoma: a novel therapeutic strategy via PI3K/AKT pathway modulation.2025Expert opinion on therapeutic targets
  9. Association between high-density lipoprotein cholesterol and 7-autoantibodies: a study on physical examination data from 2018 to 2023.2025Frontiers in endocrinology免费全文
  10. Targeted and personalized immunotherapy in lung adenocarcinoma: single-cell RNA sequencing of MAFF+ tumor cells and the therapeutic potential of FOS.2025Frontiers in immunology免费全文
  11. Tri-Compartmental Restriction Spectrum Imaging Based on 18F-FDG PET/MR for Identification of Primary Benign and Malignant Lung Lesions.2025Journal of magnetic resonance imaging : JMRI
  12. Assessment of Lung Nodule Detection and Lung CT Screening Reporting and Data System Classification Using Zero Echo Time Pulmonary MRI.2025Journal of magnetic resonance imaging : JMRI
  13. Multiparametric 18F-FDG PET/MRI based on restrictive spectrum imaging and amide proton transfer-weighted imaging facilitates the assessment of lymph node metastases in non-small cell lung cancer.2025La Radiologia medica
  14. Exploring the mechanism of the potential effects of Liujunzi Tang combined with Suanzaoren Tang in the treatment of lung cancer with insomnia based on network pharmacology and molecular docking technology.2025Medicine免费全文
  15. CXCR1 and CXCR2 Antagonism with G31P Attenuates Chemotherapy-Induced Lung Inflammation and Augments the Gefitinib Therapeutic Response in Lung Cancer.2025Oncology research免费全文
  16. Feedforward control with personalized nursing measures on respiratory function and psychological status in patients with advanced lung cancer.2025Scientific reports免费全文
  17. Shape sensing robotic assisted bronchoscopy versus virtual bronchoscopic navigation in the diagnosis of peripheral pulmonary nodules.2025Scientific reports免费全文
  18. The prognostic value of sarcopenia and sarcopenic obesity in patients with lung cancer receiving immunotherapy: a propensity score matching study.2025The oncologist免费全文
  19. Effects of penehyclidine hydrochloride on postoperative nausea and vomiting in patients who underwent radical thoracoscopic lung cancer surgery: study protocol for a single-center, prospective, randomized controlled clinical trial.2025Trials免费全文
  20. Patients outcomes in lung adenocarcinoma transforming to small-cell lung cancer after tyrosine kinase inhibitor therapy.2025World journal of surgical oncology免费全文
  21. Predictive value of metabolic parameters and apparent diffusion coefficient derived from 18F-FDG PET/MR in patients with non-small cell lung cancer.2024BMC medical imaging免费全文
  22. Effect of age on postoperative 24-hour moderate-to-severe pain after radical resection of lung cancer-specific pain in the post-anaesthesia care unit: a single-centre retrospective cohort study.2024BMJ open免费全文
  23. The deubiquitinating protein OTUD6B promotes lung adenocarcinoma progression by stabilizing RIPK1.2024Biology direct免费全文
  24. The Correlation Between the Natural Course, Pathologic Properties With Ki-67 Expression in Lung Adenocarcinoma Presenting as Ground-Glass Nodules.2024Cancer medicine免费全文
  25. Reporting quality evaluation of clinical practice guidelines for pulmonary nodules with the RIGHT checklist.2024Chinese medical journal免费全文
  26. An [18F]FDG PET/3D-ultrashort echo time MRI-based radiomics model established by machine learning facilitates preoperative assessment of lymph node status in non-small cell lung cancer.2024European radiology
  27. CD146 Promotes EMT-Mediated Migration and Invasion of NSCLC via PI3K/Akt Signaling Pathway.2024Frontiers in bioscience (Landmark edition)
  28. Effect of multidisciplinary team-style continuity of care and nutritional nursing on lung cancer: randomized study.2024Future oncology (London, England)RCT免费全文
  29. Comprehensive analysis of single-cell transcriptomics and genetic factors reveals the mechanisms and preventive strategies for the progression from pulmonary fibrosis to lung cancer.2024International immunopharmacology
  30. Effect of preoperative natural killer cell on postoperative pulmonary complications in patients of lung cancer - A single-center retrospective cohort study.2024International immunopharmacology
  31. SFXN1-mediated immune cell infiltration and tumorigenesis in lung adenocarcinoma: A potential therapeutic target.2024International immunopharmacology
  32. Multiple primary lung cancer: Updates and perspectives.2024International journal of cancer
  33. Prognostic and onco-immunological value of immune-related eRNAs-driven genes in lung adenocarcinoma.2024Journal of cancer research and clinical oncology免费全文
  34. Amide Proton Transfer-Weighted Imaging and Multiple Models Intravoxel Incoherent Motion-Based 18F-FDG PET/MRI for Predicting Progression-Free Survival in Non-Small Cell Lung Cancer.2024Journal of magnetic resonance imaging : JMRI
  35. Attention pyramid pooling network for artificial diagnosis on pulmonary nodules.2024PloS one免费全文
  36. Endobronchial Ultrasound-Based Support Vector Machine Model for Differentiating between Benign and Malignant Mediastinal and Hilar Lymph Nodes.2024Respiration; international review of thoracic diseases
  37. Advances in the Treatment of Pulmonary Nodules.2024Respiration; international review of thoracic diseases
  38. Fear of progression among postoperative patients with newly diagnosed lung cancer: a cross-sectional survey in China.2023BMC psychology免费全文
  39. Building Awareness of Diagnosis Together: Ambiguity During Progression-Free Survival Experienced by Patients With Lung Cancer and Caregivers in China.2023Cancer nursing
  40. Comparative immunological landscape between pre- and early-stage LUAD manifested as ground-glass nodules revealed by scRNA and scTCR integrated analysis.2023Cell communication and signaling : CCS免费全文
  41. Bronchoscopic transparenchymal nodule access in the diagnosis and management of pulmonary nodules.2023Chinese medical journal免费全文
  42. Impact of TP53 Mutations on EGFR-Tyrosine Kinase Inhibitor Efficacy and Potential Treatment Strategy.2023Clinical lung cancer
  43. Construction and validation of an efferocytosis-related prognostic signature in lung adenocarcinoma.2023Journal of cancer research and clinical oncology免费全文
  44. Feasibility and Safety of Endosonography-Guided Transvascular Needle Aspiration in the Diagnosis of Thoracic and Abdominal Lesions: A Meta-Analysis.2023Respiration; international review of thoracic diseases
  45. A pan-cancer analysis of potassium channel tetramerization domain containing 12 in human cancer.2023Scientific reports免费全文
  46. A diagnostic classification of lung nodules using multiple-scale residual network.2023Scientific reports免费全文
  47. Transcriptome analysis reveals the differential inflammatory effects between propofol and sevoflurane during lung cancer resection: a randomized pilot study.2023World journal of surgical oncologyRCT免费全文
  48. Extrinsic emotional regulation experienced by lung cancer patients and their family caregivers during progression-free survival.2022European journal of cancer care
  49. Identifying the individual metabolic abnormities from a systemic perspective using whole-body PET imaging.2022European journal of nuclear medicine and molecular imaging免费全文
  50. Aumolertinib Effectively Reduces Clinical Symptoms of an EGFR L858R-Mutant Non-Small Cell Lung Cancer Case Coupled With Osimertinib-Induced Cardiotoxicity: Case Report and Review.2022Frontiers in endocrinology免费全文
  51. Identification of Benign and Malignant Lung Nodules in CT Images Based on Ensemble Learning Method.2022Interdisciplinary sciences, computational life sciences
  52. Application of Simultaneous 18 F-FDG PET With Monoexponential, Biexponential, and Stretched Exponential Model-Based Diffusion-Weighted MR Imaging in Assessing the Proliferation Status of Lung Adenocarcinoma.2022Journal of magnetic resonance imaging : JMRI
  53. Evaluation of Amide Proton Transfer-Weighted Imaging for Lung Cancer Subtype and Epidermal Growth Factor Receptor: A Comparative Study With Diffusion and Metabolic Parameters.2022Journal of magnetic resonance imaging : JMRI
  54. Application of rapid rehabilitation surgical concept in perioperative nursing of patients undergoing single-port thoracoscopic lobectomy.2022Minerva medica
  55. Effects of serratus anterior plane block and thoracic paravertebral nerve block on analgesia, immune function and serum tumor markers in patients after thoracoscopic radical resection of lung cancer.2022Nagoya journal of medical scienceRCT免费全文
  56. Diagnostic value of LungPoint navigation combined with EBUS-GS & ROSE in peripheral pulmonary nodules.2022The Indian journal of medical research免费全文
  57. Lotus leaf flavonoids induce apoptosis of human lung cancer A549 cells through the ROS/p38 MAPK pathway.2021Biological research免费全文
  58. Angio-associated migratory cell protein (AAMP) interacts with cell division cycle 42 (CDC42) and enhances migration and invasion in human non-small cell lung cancer cells.2021Cancer letters
  59. LncRNA GAS6-AS2 promotes non-small-cell lung cancer cell proliferation via regulating miR-144-3p/ MAPK6 axis.2021Cell cycle (Georgetown, Tex.)免费全文
  60. Risk assessment of malignancy in solitary pulmonary nodules in lung computed tomography: a multivariable predictive model study.2021Chinese medical journal免费全文
  61. Clinical and functional significance of a novel ferroptosis-related prognosis signature in lung adenocarcinoma.2021Clinical and translational medicine免费全文
  62. Total-body dynamic PET/CT of micro-metastatic lymph node in a patient with lung cancer.2021European journal of nuclear medicine and molecular imaging
  63. Natural killer cell exhaustion in lung cancer.2021International immunopharmacology
  64. Exosomal miR-4443 promotes cisplatin resistance in non-small cell lung carcinoma by regulating FSP1 m6A modification-mediated ferroptosis.2021Life sciences
  65. Circ_0089823 reinforces malignant behaviors of non-small cell lung cancer by acting as a sponge for microRNAs targeting SOX4.2021Neoplasia (New York, N.Y.)免费全文
  66. Propofol suppresses lung cancer tumorigenesis by modulating the circ-ERBB2/miR-7-5p/FOXM1 axis.2021Thoracic cancer免费全文
中文论文(未计入)8
  1. [Male non gestational choriocarcinoma with widespread systemic metastasis: report of two cases].2025Zhonghua bing li xue za zhi = Chinese journal of pathology
  2. [circDDX17 targets miR-223-3p / RIP3 to regulate the proliferation and apoptosis of non-small cell lung cancer cells].2024Zhonghua zhong liu za zhi [Chinese journal of oncology]
  3. [Primary synovial sarcoma of lung: a clinicopathological analysis of 12 cases].2023Zhonghua bing li xue za zhi = Chinese journal of pathology
  4. [Clinicopathological features of lung adenocarcinoma with mesothelioma like growth pattern: report of three cases].2021Zhonghua bing li xue za zhi = Chinese journal of pathology
  5. [Clinical characteristics of anti-CV2 antibody-associated neurological diseases].2021Zhonghua yi xue za zhi
  6. [Clinical features and prognosis of patients with leptomeningeal metastases].2021Zhonghua yi xue za zhi
  7. [The influence of cachexia on the immunotherapy efficacy of Sintilimab for non-small cell lung cancer].2021Zhonghua zhong liu za zhi [Chinese journal of oncology]
  8. [Triptolide increases the radiosensitivity of lung cancer cells by inhibiting DNA repair and inducing apoptosis].2021Zhonghua zhong liu za zhi [Chinese journal of oncology]
它在 ClinicalTrials.gov 上的全部试验(任何状态)25
  1. Study of Anlotinib Combined With Pemetrexed in Patients With Advanced Nonsquamous NSCLC状态不明NCT03778138牵头方II期2019-01 启动
  2. Conmana Combined With Thalidomide to Treat NSCLC状态不明NCT02778893牵头方IV期2016-03 启动
  3. A Phase II Trial of LM103 for Adjuvant Treatment in Patients With Non-small Cell Lung Cancer正在招募NCT07444437研究中心II期2026-02 启动
  4. RC148 Plus Platinum-Based Chemotherapy vs Tislelizumab Plus Platinum-Based Chemotherapy for First-Line Squamous Non-Small Cell Lung Cancer (sqNSCLC)正在招募NCT07416474研究中心III期2026-04 启动
  5. Pragmatic AI-Assisted Lung Cancer Translational Study正在招募NCT07941128研究中心不分期2026-08 启动
  6. A Study Comparing TAK-928 With Docetaxel in Adults With Non-Small Cell Lung Cancer正在招募NCT07217301研究中心III期2025-11 启动
  7. Novel Thin Bronchoscope Versus Ultrathin Bronchoscope for the Diagnosis of Peripheral Pulmonary Nodules即将招募NCT07135297研究中心不分期2025-09 启动
  8. Transthoracic vs Transbronchial Cryoablation for Early-stage Peripheral Lung Cancer正在招募NCT06572540研究中心不分期2024-09 启动
  9. D-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standard Therapy Failure正在招募NCT06300177研究中心III期2024-03 启动
  10. A Dose-escalation and Dose-expansion Phase I/Phase II Clinical Study of Dositinib Mesylate Tablets (90-1408) in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer With Positive EGFR Mutation正在招募NCT07231068研究中心I/II期2022-10 启动
  11. Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors正在招募NCT04930432研究中心I/II期2021-09 启动
  12. Carboplatin/Cisplatin + Etoposide + Benmelstobart Sequential Benmelstobart Combined With Anlotinib Versus Carboplatin/Cisplatin + Etoposide + Tislelizumab Sequential Tislelizumab in the Treatment of Extensive Stage Small Cell Lung Cancer已终止NCT06897579研究中心II期2025-04 启动
  13. A Study of Efbemalenograstim Alfa Injection for Stage IIIB or IV NSCLC Recieving Moderate-risk Febrile Neutropenia (FN) Chemotherapy Regimen With Risk Factors状态不明NCT06143735研究中心II期2023-12 启动
  14. IN10018 Combination Therapy in Treatment-naïve ES-SCLC进行中,不再招募NCT06030258研究中心I/II期2023-10 启动
  15. Low-dose Radiotherapy Combined With Durvalumab, Chemotherapy(EP) in the Treatment of ES-SCLC进行中,不再招募NCT05092412研究中心II期2022-03 启动
  16. HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy进行中,不再招募NCT05338970研究中心III期2022-07 启动
  17. A Study of Lorlatinib in Subjects With ROS1-Positive Non-Small Cell Lung Cancer进行中,不再招募NCT05297890研究中心II期2022-05 启动
  18. A Real-world Study of Adjuvant Therapy in Early Stage NSCLC With EGFR Mutation-Positive in China已完成NCT04830826研究中心2020-07 启动
  19. Platinum-Based Chemotherapy With/Without INCMGA00012, an Anti-PD-1 Antibody, in Non-Small Cell Lung Cancer已完成NCT04205812研究中心III期2020-09 启动
  20. Early Cancer Detection Test - Lung Cancer China状态不明NCT04216511研究中心2019-08 启动
  21. A Study of APG-1252 Plus Osimertinib(AZD9291) in EGFR TKI Resistant NSCLC Patients已完成NCT04001777研究中心I期2019-07 启动
  22. Safety and Efficacy Study of TQ-B3101 in Patients With ROS1-positive Non-Small Cell Lung Cancer (NSCLC)状态不明NCT03972189研究中心II期2019-07 启动
  23. A Study of SHR-1210 in Combination With Carboplatin + Paclitaxel in Subjects With Squamous NSCLC状态不明NCT03668496研究中心III期2018-11 启动
  24. Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure (LUNAR)已完成NCT02973789研究中心III期2016-12 启动
  25. Risk Stratification of Patients Using the Lung Cancer Biomarker Panel in China已完成NCT01928836研究中心2012-10 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

胰腺癌

Pancreatic cancer

2021–2025 年中国大陆作者发表的 5,743 篇胰腺癌 PubMed 英文论文中,这家医院牵头了 13 篇,占 0.2%。

牵头论文
13
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 2220212022: 2220222023: 4420232024: 0020242025: 442025

郑州有 3 家医院列在胰腺癌下全国有 192 家医院列在胰腺癌下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月18日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Treatment of Irinotecan Hydrochloride Liposome Injection II in China: a Real World Study of Pancreatic Cancer Patients
    分期
    未注明
    开始
    2024-04
    发布
    登记号
    NCT06375473

    年龄 18 岁 至 100 岁(登记的条件)

    牵头:北京协和医院;另有 7 家列出的医院为研究中心上海、北京、南宁、合肥、宁波、武汉、郑州

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
论文中的科室普外/肝胆胰外科消化/肝病科肿瘤内科影像/核医学科

这些论文过半是实验室或动物研究。

牵头的论文13
  1. Astragaloside IV promotes the apoptosis of pancreatic cancer cells by activating endoplasmic reticulum stress through the PERK/ATF4/CHOP signaling pathway.2026Molecular medicine reports免费全文
  2. Comprehensive bioinformatics analysis of the prognostic value and immune infiltration of CAPN2 in pancreatic adenocarcinoma.2025Gene
  3. SPP1 + macrophages facilitate pancreatic cancer progression via ITGB6-mediated interactions: evidence from integrated multi-omics analysis and experimental validation.2025Immunologic research
  4. Multi-omics integration and machine learning uncover molecular basal-like subtype of pancreatic cancer and implicate A2ML1 in promoting tumor epithelial-mesenchymal transition.2025Journal of translational medicine免费全文
  5. PLK1 inhibition enhances gemcitabine-induced apoptosis through PLK1-dependent ERK1/2-Bim and AKT1/Noxa signals in pancreatic cancer cells.2025Medical oncology (Northwood, London, England)免费全文
  6. Immortalization-upregulated protein promotes pancreatic cancer progression by regulating NPM1/FHL1-mediated cell-cycle-checkpoint protein activity.2023Cell biology and toxicology免费全文
  7. Identification of a potential prognostic model combining pyroptosis-related gene with immune microenvironment for pancreatic ductal adenocarcinoma.2023Journal of cancer research and clinical oncology免费全文
  8. Integrin αvβ3 and EGFR dual-targeted [64Cu]Cu-NOTA-RGD-GE11 heterodimer for PET imaging in pancreatic cancer mouse model.2023Nuclear medicine and biology
  9. A pan-cancer analysis of potassium channel tetramerization domain containing 12 in human cancer.2023Scientific reports免费全文
  10. The clinical significance of circulating tumor cells and T lymphocyte subtypes in pancreatic cancer patients.2022Bioengineered免费全文
  11. Identifying cancer cell-secreted proteins that activate cancer-associated fibroblasts as prognostic factors for patients with pancreatic cancer.2022Journal of cellular and molecular medicine免费全文
  12. Clinical features and prognostic factors of elderly patients with metastatic pancreatic cancer: a population-based study.2021Aging免费全文
  13. Predictive significance of tumor budding in postoperative liver metastasis of pancreatic neuroendocrine tumors.2021Journal of surgical oncology
它在 ClinicalTrials.gov 上的全部试验(任何状态)2
  1. Treatment of Irinotecan Hydrochloride Liposome Injection II in China: a Real World Study of Pancreatic Cancer Patients正在招募NCT06375473研究中心2024-04 启动
  2. Effect of Tumor Treating Fields (TTFields, 150 kHz) as Front-Line Treatment of Locally-advanced Pancreatic Adenocarcinoma Concomitant With Gemcitabine and Nab-paclitaxel (PANOVA-3)已完成NCT03377491研究中心III期2018-05 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

乳腺癌

Breast cancer

2021–2025 年中国大陆作者发表的 16,974 篇乳腺癌 PubMed 英文论文中,这家医院牵头了 39 篇,占 0.2%。

牵头论文
39
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
4
由其他机构牵头
每年牵头的论文数
2021: 141420212022: 6620222023: 4420232024: 7720242025: 772025

郑州有 3 家医院列在乳腺癌下全国有 219 家医院列在乳腺癌下

这家医院参与的开放试验 4

依据 ClinicalTrials.gov 在 2026年11月18日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    SMP-656 for HER2-Positive Advanced Breast Cancer
    分期
    II期
    开始
    2026-08
    发布
    登记号
    NCT07726342

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 15 家列出的医院为研究中心北京、南京、合肥、广州、成都、杭州、武汉、沈阳、济南、石家庄、西安、郑州、长沙

  2. 正在招募
    A Study of BL-M07D1 With or Without Pertuzumab Versus Docetaxel + Carboplatin + Trastuzumab + Pertuzumab in Neoadjuvant Therapy for HER2-Positive Breast Cancer
    分期
    II/III期
    开始
    2025-06
    发布
    登记号
    NCT06891833

    年龄 18 岁 至 75 岁;仅女性(登记的条件)

    牵头方不是列出的医院;另有 26 家列出的医院为研究中心上海、南宁、南昌、合肥、哈尔滨、天津、太原、安阳、广州、成都、杭州、洛阳、济南、海口、深圳、石家庄、福州、蚌埠、西安、郑州、重庆、长沙

  3. 正在招募
    A Study to Assess the Effectiveness of Trastuzumab Deruxtecan in Chinese Breast Cancer Patients (REFRESH)
    分期
    未注明
    开始
    2024-01
    发布
    登记号
    NCT06210776

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 41 家列出的医院为研究中心上海、乌鲁木齐、佛山、北京、南京、南昌、南通、合肥、哈尔滨、唐山、天津、太原、广州、徐州、成都、新乡、昆明、杭州、汕头、沈阳、洛阳、深圳、潍坊、珠海、福州、西安、郑州、银川、青岛

  4. 正在招募
    Effect of Huaier Granule on Adjuvant Treatment for High-risk Early-stage Triple-negative Breast Cancer
    分期
    IV期
    开始
    2021-06
    发布
    登记号
    NCT04790305

    年龄 18 岁 至 70 岁(登记的条件)

    牵头:复旦大学附属肿瘤医院;另有 26 家列出的医院为研究中心上海、北京、南京、合肥、宁波、广州、扬州、武汉、沈阳、济南、石家庄、福州、苏州、西安、郑州、重庆、长春、长沙、青岛

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
论文中的科室病理/检验科影像/核医学科肿瘤内科普外/肝胆胰外科
牵头的论文39
  1. ATM promotes bone metastatic propensity of breast cancer by inducing osteoclastogenesis via the NFκB-CCL2 pathway.2026Acta pharmacologica Sinica
  2. Identification of risk factors and development of predictive models for chronic postsurgical pain after modified radical mastectomy.2025Annals of medicine免费全文
  3. Predictive value of shear wave elastography and molecular subtypes for postoperative efficacy in patients with early breast cancer.2025Annals of medicine免费全文
  4. The chain mediating effects of psychological resilience and family support on the association between taste alteration and cancer anorexia among Chinese breast cancer patients undergoing chemotherapy: a cross-sectional study.2025BMC psychology免费全文
  5. FATE1: A cancer testis antigen with oncogenic functions - Prognostic biomarker and JAK2/STAT1-driven autophagy regulator in breast cancer.2025Biochemical and biophysical research communications
  6. FAT1 functions as an oncogenic driver in triple negative breast cancer through AKT pathway-driven effects on the matrisome.2025International journal of biological sciences免费全文
  7. Spinal Metastasis Pain Surveillance: A Comprehensive Imaging-Based Tool Design for Evaluating Metastatic Burden and Guiding Therapeutic Strategies.2025International journal of medical sciences免费全文
  8. Appraising histone H4 lysine 5 lactylation as a novel biomarker in breast cancer.2025Scientific reports免费全文
  9. 18F-Radiolabeling and Evaluation of an AMD3465 Derivative for PET Imaging of CXCR4 in a Mouse Breast Tumor Model.2024Bioconjugate chemistry
  10. Clinicopathological characteristics and value of HER2-low expression evolution in breast cancer receiving neoadjuvant chemotherapy.2024Breast (Edinburgh, Scotland)免费全文
  11. Development and Validation of a Nomogram for Predicting Breast Malignancy in Male Patients Based on Clinical and Ultrasound Features.2024Current radiopharmaceuticals
  12. Functional evaluation of dendritic cells and extracellular vesicles as immunotherapy for breast cancer.2024Oncogene免费全文
  13. Preoperative Radiotherapy Does Not Change the Existing Treatment Paradigm in Stage III Breast Cancer.2024Oncology
  14. LINC-PINT suppresses breast cancer cell proliferation and migration via MEIS2/PPP3CC/NF-κB pathway by sponging miR-576-5p.2024The American journal of the medical sciences
  15. Excessive glutathione intake contributes to chemotherapy resistance in breast cancer: a propensity score matching analysis.2024World journal of surgical oncology免费全文
  16. Brain metastasis in de novo stage IV breast cancer.2023Breast (Edinburgh, Scotland)免费全文
  17. Outcome and Cost-Effectiveness Analysis of Long-acting G-CSF as Primary Prophylaxis of Neutropenia Induced by Chemotherapy in Breast Cancer Patients, From a Retrospective Study.2023Cancer control : journal of the Moffitt Cancer Center免费全文
  18. Oxygen-independent alkyl radical nanogenerator enhances breast cancer therapy.2023Nanomedicine : nanotechnology, biology, and medicine
  19. A pan-cancer analysis of potassium channel tetramerization domain containing 12 in human cancer.2023Scientific reports免费全文
  20. Clinical, Pathological Complete Response, and Prognosis Characteristics of HER2-Low Breast Cancer in the Neoadjuvant Chemotherapy Setting: A Retrospective Analysis.2022Annals of surgical oncology
  21. KDM3B-ETF1 fusion gene downregulates LMO2 via the WNT/β-catenin signaling pathway, promoting metastasis of invasive ductal carcinoma.2022Cancer gene therapy
  22. Long non-coding RNA DLEU1 promotes malignancy of breast cancer by acting as an indispensable coactivator for HIF-1α-induced transcription of CKAP2.2022Cell death & disease免费全文
  23. HER2-low expression does not affect the clinical outcomes of metastatic breast cancer treated with CDK4/6 inhibitor: A real-world study.2022Frontiers in endocrinology免费全文
  24. LncRNA CASC15 regulates breast cancer cell stemness via the miR-654-5p/MEF2D axis.2022Journal of biochemical and molecular toxicology
  25. Adjuvant postmastectomy radiotherapy might be associated with better survival in women with heart failure receiving total mastectomy.2022Radiation oncology (London, England)免费全文
  26. Radiomics Signatures Based on Multiparametric MRI for the Preoperative Prediction of the HER2 Status of Patients with Breast Cancer.2021Academic radiology
  27. Polymorphisms in lncRNA MIR2052HG and susceptibility to breast cancer in Chinese population.2021Aging免费全文
  28. Removal of palpable lymph nodes during sentinel lymph node biopsy in breast cancer: Our experience.2021Asian journal of surgery
  29. Development and validation of nomograms for predicting axillary non-SLN metastases in breast cancer patients with 1-2 positive sentinel lymph node macro-metastases: a retrospective analysis of two independent cohorts.2021BMC cancer免费全文
  30. FGFR1 overexpression renders breast cancer cells resistant to metformin through activation of IRS1/ERK signaling.2021Biochimica et biophysica acta. Molecular cell research
  31. Identification of a prognostic chemoresistance-related gene signature associated with immune microenvironment in breast cancer.2021Bioengineered免费全文
  32. Paravertebral block in regional anesthesia with propofol sedation reduces locoregional recurrence in patients with breast cancer receiving breast conservative surgery compared with volatile inhalational without propofol in general anesthesi2021Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  33. FGFR1 Overexpression Induces Cancer Cell Stemness and Enhanced Akt/Erk-ER Signaling to Promote Palbociclib Resistance in Luminal A Breast Cancer Cells.2021Cells免费全文
  34. Preparation and evaluation of ultrasound-mediated dual-targeted theragnostic systems utilising phase-changeable polymeric nanodroplets on the integrin αν β3 overexpressed breast cancer.2021Clinical and translational medicine免费全文
  35. A comparative study of the value of amide proton transfer-weighted imaging and diffusion kurtosis imaging in the diagnosis and evaluation of breast cancer.2021European radiology
  36. Neoadjuvant Chemotherapy or Endocrine Therapy for Invasive Ductal Carcinoma of the Breast With High Hormone Receptor Positivity and Human Epidermal Growth Factor Receptor 2 Negativity.2021JAMA network open免费全文
  37. Long non-coding RNA ROR recruits histone transmethylase MLL1 to up-regulate TIMP3 expression and promote breast cancer progression.2021Journal of translational medicine免费全文
  38. SAP-cGAN: Adversarial learning for breast mass segmentation in digital mammogram based on superpixel average pooling.2021Medical physics
  39. Pathologic response rates for breast cancer stages as a predictor of outcomes in patients receiving neoadjuvant chemotherapy followed by breast-conserving surgery.2021Surgical oncology
中文论文(未计入)1
  1. [Prospective comparative study of breast reconstruction with dual plane prosthesis implantation and anterior pectoralis prosthesis implantation under endoscopy].2024Zhongguo xiu fu chong jian wai ke za zhi = Zhongguo xiufu chongjian waike zazhi = Chinese journal of reparative and reconstructive surgery免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)10
  1. SMP-656 for HER2-Positive Advanced Breast Cancer正在招募NCT07726342研究中心II期2026-08 启动
  2. A Study of BL-M07D1 With or Without Pertuzumab Versus Docetaxel + Carboplatin + Trastuzumab + Pertuzumab in Neoadjuvant Therapy for HER2-Positive Breast Cancer正在招募NCT06891833研究中心II/III期2025-06 启动
  3. A Study to Assess the Effectiveness of Trastuzumab Deruxtecan in Chinese Breast Cancer Patients (REFRESH)正在招募NCT06210776研究中心2024-01 启动
  4. Effect of Huaier Granule on Adjuvant Treatment for High-risk Early-stage Triple-negative Breast Cancer正在招募NCT04790305研究中心IV期2021-06 启动
  5. A Study of SHR-A1811 Combined With Capecitabine in Treatment of Unresectable or Metastatic Breast Cancer With Low HER2 Expression.状态不明NCT05845138研究中心I/II期2023-07 启动
  6. FS-1502 Versus T-DM1 for HER2-Positive Unresectable Locally Advanced or Metastatic Breast Cancer状态不明NCT05755048研究中心III期2023-03 启动
  7. A Study to Evaluate the Efficacy and Safety of HLX11 vs. EU-Perjeta® in the Neoadjuvant Therapy of HER2-Positive and HR-Negative Early-stage or Locally Advanced Breast Cancer进行中,不再招募NCT05346224研究中心III期2022-04 启动
  8. A Study of Mitoxantrone Hydrochloride Liposome Injection in Patients With Advanced HER2 Negative Breast Cancer已终止NCT04927481研究中心II期2021-06 启动
  9. Toripalimab in Combination With Nab-Paclitaxel For Patients With Metastatic or Recurrent Triple-Negative Breast Cancer (TNBC) With or Without Systemic Treatment已完成NCT04085276研究中心III期2018-12 启动
  10. Aromasin® Interventional Study Of Early Invasive Breast Cancer Patients In China已完成NCT01176916研究中心IV期2011-02 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

胶质瘤

Glioma

2021–2025 年中国大陆作者发表的 7,081 篇胶质瘤 PubMed 英文论文中,这家医院牵头了 56 篇,占 0.8%。

牵头论文
56
2021–2025 年
牵头试验
8
任何状态,ClinicalTrials.gov
牵头的开放试验
6
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 9920212022: 171720222023: 101020232024: 7720242025: 10102025

郑州有 6 家医院列在胶质瘤下全国有 187 家医院列在胶质瘤下

这家医院参与的开放试验 6

依据 ClinicalTrials.gov 在 2026年11月18日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Sintilimab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for ctDNAlevel- Relapse and Clinical-relapse Oligodendroglioma
    分期
    II期
    开始
    2022-12
    发布
    登记号
    NCT05512351

    年龄 18 岁 至 未注明(登记的条件)

    牵头:河南省人民医院郑州

  2. 即将招募
    Tislelizumab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for Bevacizumab Refractory Recurrent Glioblastoma
    分期
    II期
    开始
    2023-10
    发布
    登记号
    NCT05540275

    年龄 18 岁 至 未注明(登记的条件)

    牵头:河南省人民医院郑州

  3. 即将招募
    Sintilimab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for ctDNA-level-relapse and Clinical-relapse Glioblastoma
    分期
    II期
    开始
    2022-12
    发布
    登记号
    NCT05502991

    年龄 18 岁 至 未注明(登记的条件)

    牵头:河南省人民医院郑州

  4. 即将招募
    Study on Gene Evolution in Glioma Under Stress Therapy
    分期
    未注明
    开始
    2022-12
    发布
    登记号
    NCT05512325

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:河南省人民医院郑州

  5. 即将招募
    Correlation Between Psychological Stress and Progression of Diffuse Astrocytoma Towards Secondary Glioma
    分期
    未注明
    开始
    2022-12
    发布
    登记号
    NCT05532969

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:河南省人民医院郑州

  6. 即将招募
    Radiogenomics in Glioblastoma: Correlation Between Multiparametric Imaging Biomarkers and Genetic Biomarkers
    分期
    未注明
    开始
    2022-12
    发布
    登记号
    NCT05541042

    年龄 18 岁 至 未注明(登记的条件)

    牵头:河南省人民医院郑州

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
论文中的科室神经外科影像/核医学科肿瘤内科病理/检验科

这些论文过半是实验室或动物研究。

牵头的论文56
  1. Integrated single-cell and spatial transcriptomics uncover the prognostic, epigenetic, and immunological roles of FANCC in low-grade glioma.2026Neurological research
  2. FAM111B as a biomarker influences the prognosis and immune microenvironment of low-grade gliomas.2026Neurological research
  3. PSMC3IP as a prognostic biomarker and immunomodulatory regulator in low-grade glioma: insights from multi-omics and methylation analysis.2026Neurological research
  4. Comprehensive multicentre retrospective analysis for predicting isocitrate dehydrogenase-mutant lower-grade gliomas.2025Annals of clinical and translational neurology免费全文
  5. POLD3 knockdown effects on low-grade glioma: insights from bioinformatics and experimental validation.2025BMC cancer免费全文
  6. Causal Association Between Immune Cell Traits and Risk of Multiple Malignant and Nonmalignant CNS Diseases: A Mendelian Randomization and Single-Cell Transcriptomic Analysis.2025Brain and behavior免费全文
  7. Dynamic Monitoring of Circulating Tumor DNA to Predict the Risk of Non In Situ Recurrence of Postoperative Glioma: A Prospective Cohort Study.2025Cancer medicine免费全文
  8. Development of a web-based tool for estimating individualized survival curves in glioblastoma using clinical, mRNA, and tumor microenvironment features with fusion techniques.2025Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  9. The oncogenic role of CCDC34 in lower-grade gliomas: prognostic significance and therapeutic potential.2025Journal of neuro-oncology免费全文
  10. Sulforaphane-cysteine inhibits α-tubulin/PD-L1/PFKFB4 axis leading to apoptosis in human glioblastoma.2025Medical oncology (Northwood, London, England)
  11. HERC5/ISG15 Enhances Glioblastoma Stemness and Tumor Progression by mediating SERBP1protein stability.2025Neuromolecular medicine
  12. Dynamic Tumor in Situ Fluid Circulating Tumor DNA Postsurgery Effectively Predicts Recurrence and Clinical Benefits for Glioblastomas.2025Neurosurgery免费全文
  13. Zinc finger protein 800 (ZNF800) promotes proliferation and migration of lower-grade glioma and is associated with immune infiltration.2025PloS one免费全文
  14. DSN1 may predict poor prognosis of lower-grade glioma patients and be a potential target for immunotherapy.2024Cancer biology & therapy免费全文
  15. Assessment of MGMT promoter methylation status in glioblastoma using deep learning features from multi-sequence MRI of intratumoral and peritumoral regions.2024Cancer imaging : the official publication of the International Cancer Imaging Society免费全文
  16. Predicting recurrent glioblastoma clinical outcome to immune checkpoint inhibition and low-dose bevacizumab with tumor in situ fluid circulating tumor DNA analysis.2024Cancer immunology, immunotherapy : CII免费全文
  17. WD repeat domain 76 predicts poor prognosis in lower grade glioma and provides an original target for immunotherapy.2024European journal of medical research免费全文
  18. TME-Activated MnO2/Pt Nanoplatform of Hydroxyl Radical and Oxygen Generation to Synergistically Promote Radiotherapy and MR Imaging of Glioblastoma.2024International journal of nanomedicine免费全文
  19. Dynamics of tumor in situ fluid circulating tumor DNA in recurrent glioblastomas forecasts treatment efficacy of immune checkpoint blockade coupled with low-dose bevacizumab.2024Journal of cancer research and clinical oncology免费全文
  20. Synthesis of gadolinium-enhanced glioma images on multisequence magnetic resonance images using contrastive learning.2024Medical physics
  21. LncRNA-PVT1 was identified as a key regulator for TMZ resistance and STAT-related pathway in glioma.2023BMC cancer免费全文
  22. Genomic alterations of oligodendrogliomas at distant recurrence.2023Cancer medicine免费全文
  23. Prognostic Significance of mRNA Expression RBBP8 or Its Methylation in Gliomas.2023Cellular and molecular neurobiology免费全文
  24. Fear stress promotes glioma progression through inhibition of ferroptosis by enhancing FSP1 stability.2023Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  25. PSRC1 Regulated by DNA Methylation Is a Novel Target for LGG Immunotherapy.2023Journal of molecular neuroscience : MN
  26. RFX2 promotes tumor cell stemness through epigenetic regulation of PAF1 in spinal ependymoma.2023Journal of neuro-oncology
  27. Caspase-3 in glioma indicates an unfavorable prognosis by involving surrounding angiogenesis and tumor cell repopulation.2023Journal of neuro-oncology
  28. Granulocyte-macrophage colony stimulating factor enhances efficacy of nimustine rendezvousing with temozolomide plus irradiation in patients with glioblastoma.2023Technology and health care : official journal of the European Society for Engineering and MedicineRCT
  29. ECM2, a prognostic biomarker for lower grade glioma, serves as a potential novel target for immunotherapy.2023The international journal of biochemistry & cell biology
  30. IKBKE regulates angiogenesis by modulating VEGF expression and secretion in glioblastoma.2023Tissue & cell
  31. Berberine inhibits glioma cell migration and invasion by suppressing TGF-β1/COL11A1 pathway.2022Biochemical and biophysical research communications
  32. TGIF1 overexpression promotes glioma progression and worsens patient prognosis.2022Cancer medicine免费全文
  33. High expression of HOXA4 in patients with glioma indicates unfavorable clinical outcomes.2022Cell cycle (Georgetown, Tex.)免费全文
  34. Silencing IKBKE inhibits the migration and invasion of glioblastoma by promoting Snail1 degradation.2022Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  35. Real-time longitudinal analysis of human gliomas reveals in vivo genome evolution and therapeutic impact under standardized treatment.2022Clinical and translational medicine免费全文
  36. CLSPN is a potential biomarker associated with poor prognosis in low-grade gliomas based on a multi-database analysis.2022Current research in translational medicine
  37. Aberrantly high DEPDC1B expression leads to poor prognosis in patients with lower-grade gliomas.2022European review for medical and pharmacological sciences
  38. Identification of PYGL as a key prognostic gene of glioma by integrated bioinformatics analysis.2022Future oncology (London, England)
  39. MiR-222-3p inhibits formation of medulloblastoma stem-like cells by targeting Notch2/c-myc signaling pathway.2022Immunopharmacology and immunotoxicology
  40. Effects of ESCO2 or its methylation on the prognosis, clinical characteristics, immune microenvironment, and pathogenesis of low-grade glioma.2022International immunopharmacology
  41. ITGB3BP is a potential biomarker associated with poor prognosis of glioma.2022Journal of cellular and molecular medicine免费全文
  42. Identification of an Inflammatory Response-Related Gene Signature to Predict Survival and Immune Status in Glioma Patients.2022Journal of immunology research免费全文
  43. DRAXIN as a Novel Diagnostic Marker to Predict the Poor Prognosis of Glioma Patients.2022Journal of molecular neuroscience : MN免费全文
  44. Apatinib combined with temozolomide treatment for pseudoprogression in glioblastoma: A case report.2022Medicine免费全文
  45. Post-traumatic brain injury glioma: Characteristics, report of 2 cases report and literature review.2022Medicine免费全文
  46. A lightweight 3D UNet model for glioma grading.2022Physics in medicine and biology
  47. Long noncoding RNA SNHG9 facilitates growth of glioma stem-like cells via miR-326/SOX9 axis.2022The journal of gene medicine
  48. LINC02381 contributes to cell proliferation and hinders cell apoptosis in glioma by transcriptionally enhancing CBX5.2021Brain research bulletin
  49. Significantly high expression of NUP37 leads to poor prognosis of glioma patients by promoting the proliferation of glioma cells.2021Cancer medicine免费全文
  50. Circ-UBAP2 functions as sponges of miR-1205 and miR-382 to promote glioma progression by modulating STC1 expression.2021Cancer medicine免费全文
  51. Genome-wide CRISPR/Cas9 screening identifies CARHSP1 responsible for radiation resistance in glioblastoma.2021Cell death & disease免费全文
  52. Integrating real-time in vivo tumour genomes for longitudinal analysis and management of glioma recurrence.2021Clinical and translational medicine免费全文
  53. MYC/NBS1-Mediated DNA Damage Response is Involved in the Inhibitory Effect of Hydroxysafflor Yellow A on Glioma Cells.2021Drug design, development and therapy免费全文
  54. Exosomal transfer of miR‑25‑3p promotes the proliferation and temozolomide resistance of glioblastoma cells by targeting FBXW7.2021International journal of oncology免费全文
  55. Overexpression of GINS4 is associated with poor prognosis and survival in glioma patients.2021Molecular medicine (Cambridge, Mass.)免费全文
  56. Overexpressed XRCC2 as an independent risk factor for poor prognosis in glioma patients.2021Molecular medicine (Cambridge, Mass.)免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)9
  1. Tislelizumab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for Bevacizumab Refractory Recurrent Glioblastoma即将招募NCT05540275牵头方II期2023-10 启动
  2. Study on Gene Evolution in Glioma Under Stress Therapy即将招募NCT05512325牵头方2022-12 启动
  3. Sintilimab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for ctDNA-level-relapse and Clinical-relapse Glioblastoma即将招募NCT05502991牵头方II期2022-12 启动
  4. Correlation Between Psychological Stress and Progression of Diffuse Astrocytoma Towards Secondary Glioma即将招募NCT05532969牵头方2022-12 启动
  5. Sintilimab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for ctDNAlevel- Relapse and Clinical-relapse Oligodendroglioma正在招募NCT05512351牵头方II期2022-12 启动
  6. Radiogenomics in Glioblastoma: Correlation Between Multiparametric Imaging Biomarkers and Genetic Biomarkers即将招募NCT05541042牵头方2022-12 启动
  7. Personalized Trial in ctDNA-level-relapse Glioblastoma状态不明NCT05539339牵头方不分期2022-12 启动
  8. Correlation Between Psychological Stress and Disease Progression in Newly Diagnosed Glioblastoma Patients状态不明NCT05515133牵头方2022-12 启动
  9. Autologous CAR-T/TCR-T Cell Immunotherapy for Solid Malignancies状态不明NCT03941626研究中心I/II期2019-09 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

视网膜母细胞瘤

Retinoblastoma

2021–2025 年中国大陆作者发表的 301 篇视网膜母细胞瘤 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.7%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 1120222023: 0020232024: 0020242025: 002025

郑州有 5 家医院列在视网膜母细胞瘤下全国有 176 家医院列在视网膜母细胞瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的视网膜母细胞瘤开放试验。

这些数字背后的记录
论文中的科室眼科/神经眼科

打开 PubMed 检索ClinicalTrials.gov

癌症

脊索瘤

Chordoma

2021–2025 年没有牵头脊索瘤的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

郑州有 3 家医院列在脊索瘤下全国有 84 家医院列在脊索瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的脊索瘤开放试验。

这些数字背后的记录
早期论文(2016–2020 年)1
  1. [Chondromucinous tumors involving craniocerebral slope area: a clinicopathological analysis of eight cases].2019Zhonghua bing li xue za zhi = Chinese journal of pathology

打开 PubMed 检索ClinicalTrials.gov

癌症

骨肉瘤

Osteosarcoma

2021–2025 年中国大陆作者发表的 2,257 篇骨肉瘤 PubMed 英文论文中,这家医院牵头了 7 篇,占 0.3%。

牵头论文
7
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 2220212022: 0020222023: 2220232024: 1120242025: 222025

郑州有 8 家医院列在骨肉瘤下全国有 570 家医院列在骨肉瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的骨肉瘤开放试验。

这些数字背后的记录
论文中的科室病理/检验科

这些论文过半是实验室或动物研究。

牵头的论文7
  1. Integrating single-cell transcriptomics, molecular docking, and dynamics simulations to characterize protein kinase X-linked mechanisms in osteosarcoma.2025International journal of biological macromolecules
  2. Multomic analysis reveals the potential of LAG3 as a prognostic and immune biomarker and its validation in osteosarcoma.2025Scientific reports免费全文
  3. Exploration in the Mechanism of Ginsenoside Rg5 for the Treatment of Osteosarcoma by Network Pharmacology and Molecular Docking.2024Orthopaedic surgery免费全文
  4. DNMT1 determines osteosarcoma cell resistance to apoptosis by associatively modulating DNA and mRNA cytosine-5 methylation.2023FASEB journal : official publication of the Federation of American Societies for Experimental Biology
  5. Multiproperty Polyethylenimine-Caged Platinum Nanoclusters Promote Apoptosis of Osteosarcoma Cells via Regulating the BAX-Bcl-2/Caspase-3/PARP Axis.2023Molecular pharmaceutics
  6. Circular RNA circVRK1 suppresses the proliferation, migration and invasion of osteosarcoma cells by regulating zinc finger protein ZNF652 expression via microRNA miR-337-3p.2021Bioengineered免费全文
  7. Circ-XPR1 promotes osteosarcoma proliferation through regulating the miR-214-5p/DDX5 axis.2021Human cell
中文论文(未计入)1
  1. [The expression of neuraminidase-1 in Ewing sarcoma and its impact on sarcoma cell proliferation and migration].2023Zhonghua yi xue za zhi
早期论文(2016–2020 年)7
  1. Comprehensive Characterization of Prognostic Long Noncoding RNAs in Osteosarcoma.2020BioMed research international
  2. MicroRNA-765 targets MTUS1 to promote the progression of osteosarcoma via mediating ERK/EMT pathway.2019European review for medical and pharmacological sciences
  3. miR‑9 depletion suppresses the proliferation of osteosarcoma cells by targeting p16.2019International journal of oncology
  4. G-protein-coupled estrogen receptor suppresses the migration of osteosarcoma cells via post-translational regulation of Snail.2019Journal of cancer research and clinical oncology
  5. LncRNA SNHG15 contributes to proliferation, invasion and autophagy in osteosarcoma cells by sponging miR-141.2017Journal of biomedical science
  6. MicroRNA-139 inhibits the proliferation and migration of osteosarcoma cells via targeting forkhead-box P2.2017Life sciences
  7. Small Molecule Survivin Inhibitor YM155 Displays Potent Activity Against Human Osteosarcoma Cells.2016Cancer investigation

打开 PubMed 检索ClinicalTrials.gov

癌症

胃肠道间质瘤

Gastrointestinal stromal tumour

2021–2025 年没有牵头胃肠道间质瘤的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

郑州有 5 家医院列在胃肠道间质瘤下全国有 240 家医院列在胃肠道间质瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的胃肠道间质瘤开放试验。

这些数字背后的记录
早期论文(2016–2020 年)2
  1. Mutation of the KIT Gene, excluding Exon 11, in Gastrointestinal Stromal Tumors.2020Biomedical and environmental sciences : BES
  2. Analyzing the molecular mechanism of the tissue specificity of gastrointestinal stromal tumors by using bioinformatics approaches.2018Journal of B.U.ON. : official journal of the Balkan Union of Oncology

打开 PubMed 检索ClinicalTrials.gov

癌症

神经母细胞瘤

Neuroblastoma

2021–2025 年中国大陆作者发表的 1,132 篇神经母细胞瘤 PubMed 英文论文中,这家医院牵头了 3 篇,占 0.3%。

牵头论文
3
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 1120222023: 1120232024: 0020242025: 002025

郑州有 6 家医院列在神经母细胞瘤下全国有 321 家医院列在神经母细胞瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的神经母细胞瘤开放试验。

这些数字背后的记录
论文中的科室肿瘤内科儿科
牵头的论文3
  1. miRNA326-5p Targets DKC1 Gene to Regulate Apoptosis-Related Proteins and Intervene in the Development of Neuroblastoma.2023Analytical cellular pathology (Amsterdam)免费全文
  2. The N-Myc-responsive lncRNA MILIP promotes DNA double-strand break repair through non-homologous end joining.2022Proceedings of the National Academy of Sciences of the United States of America免费全文
  3. SOX17 inhibits proliferation and invasion of neuroblastoma through CXCL12/CXCR4 signaling axis.2021Cellular signalling
中文论文(未计入)1
  1. [PTX3 promotes proliferation, invasion and drug resistance of neuroblastoma cells in children by regulating TLR4/NF-κB signaling pathway].2021Zhonghua zhong liu za zhi [Chinese journal of oncology]
早期论文(2016–2020 年)5
  1. SNHG16 Silencing Inhibits Neuroblastoma Progression by Downregulating HOXA7 via Sponging miR-128-3p.2020Neurochemical research
  2. FGF represses metastasis of neuroblastoma regulated by MYCN and TGF-β1 induced LMO1 via control of let-7 expression.2019Brain research
  3. [PDCD4 enhances the inhibitory effect of As(2)O(3) on the growth and NF-κB signaling pathway in neuroblastoma cells].2019Zhonghua zhong liu za zhi [Chinese journal of oncology]
  4. [Effects of miR-144 on proliferation, apoptosis and cisplatin resistance by targeting MYCN in pediatric neuroblastoma].2019Zhonghua zhong liu za zhi [Chinese journal of oncology]
  5. PEST-containing nuclear protein mediates the proliferation, migration, and invasion of human neuroblastoma cells through MAPK and PI3K/AKT/mTOR signaling pathways.2018BMC cancer

打开 PubMed 检索ClinicalTrials.gov

癌症

尤文肉瘤

Ewing sarcoma

2021–2025 年没有牵头尤文肉瘤的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

郑州有 3 家医院列在尤文肉瘤下全国有 134 家医院列在尤文肉瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的尤文肉瘤开放试验。

这些数字背后的记录
中文论文(未计入)1
  1. [The expression of neuraminidase-1 in Ewing sarcoma and its impact on sarcoma cell proliferation and migration].2023Zhonghua yi xue za zhi
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. A Clinical Study of TK216 in Patients With Relapsed or Refractory Ewing's Sarcoma已完成NCT05046314研究中心II期2024-03 启动

打开 PubMed 检索ClinicalTrials.gov

血液疾病

多发性骨髓瘤

Multiple myeloma

2021–2025 年中国大陆作者发表的 1,676 篇多发性骨髓瘤 PubMed 英文论文中,这家医院牵头了 5 篇,占 0.3%。

牵头论文
5
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
2
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 0020222023: 2220232024: 0020242025: 222025

郑州有 4 家医院列在多发性骨髓瘤下全国有 175 家医院列在多发性骨髓瘤下

这家医院参与的开放试验 2

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
    分期
    I期
    开始
    2026-05
    发布
    登记号
    NCT07477587

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 46 家列出的医院为研究中心上海、北京、南京、南昌、厦门、合肥、哈尔滨、天津、太原、宁波、广州、徐州、成都、无锡、杭州、武汉、沈阳、济南、深圳、温州、潍坊、石家庄、福州、苏州、蚌埠、贵阳、郑州、重庆、长沙、青岛

  2. 即将招募
    Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple Myeloma
    分期
    III期
    开始
    2026-06
    发布
    登记号
    NCT07569757

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 38 家列出的医院为研究中心上海、兰州、北京、南京、南宁、南昌、合肥、哈尔滨、太原、广州、徐州、成都、承德、昆明、杭州、株洲、沈阳、泸州、济南、湛江、石家庄、蚌埠、西安、贵阳、郑州、重庆、长沙、青岛

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题诊断、微小残留病与危险分层复发与耐药CAR-T 与细胞治疗
牵头的论文5
  1. Long-term follow-up of patients with relapsed/refractory multiple myeloma after BCMA CAR-T-cell therapy.2025Frontiers in immunology免费全文
  2. Role of the bone marrow microenvironment in multiple myeloma: Impact of niches on drug resistance mechanisms.2025Seminars in diagnostic pathology
  3. High Red Blood Cell Distribution Width to Platelet Ratio is an Independent Poor Prognostic Factor in Patients with Newly Diagnosed Multiple Myeloma.2023Discovery medicine
  4. Pathogenesis, clinical characteristics and personalized managements of multiple myeloma with chromosome 1 abnormalities.2023Leukemia & lymphoma
  5. Combined immune score predicts the prognosis of newly diagnosed multiple myeloma patients in the bortezomib-based therapy era.2021Medicine免费全文
中文论文(未计入)4
  1. [The Value of sFLC and Serum Calcium in the Diagnosis and Prognosis of Multiple Myeloma Patients].2024Zhongguo shi yan xue ye xue za zhi
  2. [Analysis of clinical and prognostic characteristics of newly diagnosed multiple myeloma with myelofibrosis patients].2024Zhonghua yi xue za zhi
  3. [The significance of bone marrow immature plasma cell burden in the prognosis of newly diagnosed multiple myeloma patients].2022Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi免费全文
  4. [Clinical and biological characteristics and prognosis of patients with biclonal multiple myeloma].2021Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)4
  1. Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple Myeloma即将招募NCT07569757研究中心III期2026-06 启动
  2. A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma正在招募NCT07477587研究中心I期2026-05 启动
  3. A Study of NINLARO® in Chinese Adults With Multiple Myeloma进行中,不再招募NCT05013190研究中心2021-10 启动
  4. Clinical Trial to Evaluate CT053 in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 1)状态不明NCT03975907研究中心I/II期2019-06 启动

打开 PubMed 检索ClinicalTrials.gov

血液疾病

淋巴瘤

Lymphoma

2021–2025 年中国大陆作者发表的 3,830 篇淋巴瘤 PubMed 英文论文中,这家医院牵头了 13 篇,占 0.3%。

牵头论文
13
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
9
由其他机构牵头
每年牵头的论文数
2021: 5520212022: 0020222023: 0020232024: 2220242025: 662025

郑州有 4 家医院列在淋巴瘤下全国有 199 家医院列在淋巴瘤下

这家医院参与的开放试验 9

依据 ClinicalTrials.gov 在 2026年11月18日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Assessing Treatment of T-Cell Lymphoma With GW5282 in Combination With Golidocitinib (BEI-DOU3)
    分期
    I/II期
    开始
    2026-04
    发布
    登记号
    NCT07496229

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 11 家列出的医院为研究中心上海、南京、南宁、太原、成都、武汉、温州、福州、郑州、重庆

  2. 正在招募
    A Study to Evaluate the Efficacy and Safety of ICP-248 in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (APEX-06)
    分期
    II期
    开始
    2025-08
    发布
    登记号
    NCT07082686

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 27 家列出的医院为研究中心上海、乌鲁木齐、北京、南京、南宁、南昌、合肥、天津、广州、成都、杭州、武汉、济南、福州、西安、郑州、重庆、长春、长沙、青岛

  3. 正在招募
    A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell Lymphoma
    分期
    II期
    开始
    2025-11
    发布
    登记号
    NCT07189065

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 38 家列出的医院为研究中心上海、临沂、北京、南京、南宁、南昌、厦门、合肥、大连、天津、太原、广州、徐州、成都、杭州、武汉、沈阳、洛阳、石家庄、福州、苏州、郑州、重庆、长春、长沙

  4. 正在招募
    A Global Phase 3 Study of Orelabrutinib+BR Vs.BR in Pts with TN MCL
    分期
    III期
    开始
    2024-05
    发布
    登记号
    NCT06363994

    年龄 60 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 31 家列出的医院为研究中心上海、乌鲁木齐、北京、南京、南昌、合肥、天津、太原、宁波、常州、广州、成都、杭州、武汉、沈阳、洛阳、济南、石家庄、福州、蚌埠、西安、郑州、重庆、长春、长沙

  5. 正在招募
    ICP-248 in Combination With Orelabrutinib in Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (APEX-03)
    分期
    II/III期
    开始
    2024-05
    发布
    登记号
    NCT06378138

    年龄 18 岁 至 80 岁(登记的条件)

    牵头方不是列出的医院;另有 43 家列出的医院为研究中心上海、乌鲁木齐、兰州、北京、南京、南宁、南昌、厦门、合肥、大连、天津、太原、宜昌、广州、成都、杭州、武汉、沈阳、洛阳、济南、淮安、石家庄、福州、蚌埠、西安、遵义、郑州、重庆、长春、长沙

  6. 正在招募
    A Clinical Study to Evaluate the Efficacy and Safety of TQB3702 Tablets Combined With Immunochemotherapy for the Treatment of B-cell Lymphoma
    分期
    II期
    开始
    2024-11
    发布
    登记号
    NCT06566586

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 16 家列出的医院为研究中心上海、乌鲁木齐、兰州、南宁、南昌、呼和浩特、哈尔滨、天津、太原、广州、武汉、泸州、西安、郑州、长沙

  7. 正在招募
    Efficacy and Safety of Orelabrutinib Combined With Rituximab Versus Lenalidomide Combined With Rituximab in Patients With Relapsed/Refractory Marginal Zone Lymphoma
    分期
    III期
    开始
    2023-12
    发布
    登记号
    NCT06082102

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 18 家列出的医院为研究中心上海、北京、南昌、大连、广州、成都、杭州、武汉、沈阳、烟台、蚌埠、西安、郑州、长沙、青岛

  8. 即将招募
    A Phase 3 Study to Compare the Efficacy of ICP-248 in Combination With Orelabrutinib Versus Pirtobrutinib in Participants With Relapsed or Refractory Mantle Cell Lymphoma (r/r MCL).
    分期
    III期
    开始
    2026-10
    发布
    登记号
    NCT07784101

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 24 家列出的医院为研究中心上海、北京、南京、合肥、天津、广州、成都、昆明、杭州、武汉、沈阳、济南、石家庄、福州、西安、郑州、重庆、长沙

  9. 即将招募
    Orelabrutinib Plus ICP 248 vs Orelabrutinib for Relapsed/Refractory Marginal Zone Lymphoma
    分期
    III期
    开始
    2026-10
    发布
    登记号
    NCT07896590

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 40 家列出的医院为研究中心上海、兰州、北京、南京、南昌、厦门、合肥、哈尔滨、天津、太原、广州、成都、昆明、杭州、武汉、沈阳、洛阳、济南、海口、石家庄、福州、西安、郑州、重庆、长沙

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
论文中的科室病理/检验科影像/核医学科神经外科
牵头的论文13
  1. Identification of the IFN-γ/IL-4 ratio as a prognostic biomarker and development of an immune-related prognostic model in diffuse large B-cell lymphoma.2025BMC cancer免费全文
  2. New hopes and challenges in targeted therapy and immunotherapy for primary central nervous system lymphoma.2025Frontiers in immunology免费全文
  3. Comparative global burden analysis of lymphoma subtypes: a statistical evaluation of severity across global regions.2025Frontiers in public health免费全文
  4. Ferroptosis-related gene analysis revealing novel biomarkers and therapeutic targets in diffuse large B-cell lymphoma.2025Scientific reports免费全文
  5. ITK overexpression enhances T cell cytotoxicity against DLBCL through the TCR-Ca2+-Calcineurin-NFAT-IFN-γ pathway.2025Scientific reports免费全文
  6. Clinical Potential of Copy Number Aberration as a Diagnostic and Prognostic Biomarker in Lymphoma.2025Technology in cancer research & treatment免费全文
  7. Prognostic Value of 18F-FDG PET/CT Radiomics in Extranodal Nasal-Type NK/T Cell Lymphoma.2024Korean journal of radiology免费全文
  8. Comparison between Endobronchial Ultrasound-Guided Transbronchial Node Biopsy and Transbronchial Needle Aspiration: A Meta-Analysis.2024Respiration; international review of thoracic diseases
  9. NRF1-regulated CircNSUN2 promotes lymphoma progression through activating Wnt signaling pathway via stabilizing HMGA1.2021Cell cycle (Georgetown, Tex.)免费全文
  10. Long-term survival outcomes of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma: a systematic review and meta-analysis.2021European review for medical and pharmacological sciences
  11. G protein nucleolar 3 promotes Non-Hodgkin lymphoma progression by activating the Wnt/β-catenin signaling pathway.2021Experimental cell research
  12. MYC rearrangement but not extra MYC copies is an independent prognostic factor in patients with mantle cell lymphoma.2021Haematologica免费全文
  13. Self-efficacy, psychological distress, and marital quality in young and middle-aged couples facing lymphoma: The mediating effect of dyadic coping.2021Psycho-oncology
中文论文(未计入)6
  1. [Primary adrenal NK/T cell lymphoma: a clinicopathologic analysis of six cases].2023Zhonghua bing li xue za zhi = Chinese journal of pathology
  2. [Clinicopathological features of mature T/NK cell lymphoma with aberrant CD20 or CD79α expression].2022Zhonghua bing li xue za zhi = Chinese journal of pathology
  3. [Clinicopathological features and BRAF V600E and MYD88 L265P mutation status of nodal marginal zone lymphoma].2022Zhonghua bing li xue za zhi = Chinese journal of pathology
  4. [Extranodal nasal type natural killer/T-cell lymphoma of the digestive system: a clinicopathological study of thirteen cases].2021Zhonghua bing li xue za zhi = Chinese journal of pathology
  5. [The expression and prognostic value of PD-1, TIM-3, LAG-3 and BTLA in extranodal NK/T cell lymphoma].2021Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi免费全文
  6. [Efficacy and safety of PD-1 inhibitor combined with chemotherapy in the primary treatment of phase Ⅲ/Ⅳ extranodal nasal-type natural killer/T cell lymphoma].2021Zhonghua yi xue za zhi
它在 ClinicalTrials.gov 上的全部试验(任何状态)18
  1. Assessing Treatment of T-Cell Lymphoma With GW5282 in Combination With Golidocitinib (BEI-DOU3)正在招募NCT07496229研究中心I/II期2026-04 启动
  2. Orelabrutinib Plus ICP 248 vs Orelabrutinib for Relapsed/Refractory Marginal Zone Lymphoma即将招募NCT07896590研究中心III期2026-10 启动
  3. A Phase 3 Study to Compare the Efficacy of ICP-248 in Combination With Orelabrutinib Versus Pirtobrutinib in Participants With Relapsed or Refractory Mantle Cell Lymphoma (r/r MCL).即将招募NCT07784101研究中心III期2026-10 启动
  4. A Study to Evaluate the Efficacy and Safety of ICP-248 in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (APEX-06)正在招募NCT07082686研究中心II期2025-08 启动
  5. A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell Lymphoma正在招募NCT07189065研究中心II期2025-11 启动
  6. ICP-248 in Combination With Orelabrutinib in Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (APEX-03)正在招募NCT06378138研究中心II/III期2024-05 启动
  7. A Clinical Study to Evaluate the Efficacy and Safety of TQB3702 Tablets Combined With Immunochemotherapy for the Treatment of B-cell Lymphoma正在招募NCT06566586研究中心II期2024-11 启动
  8. A Global Phase 3 Study of Orelabrutinib+BR Vs.BR in Pts with TN MCL正在招募NCT06363994研究中心III期2024-05 启动
  9. Efficacy and Safety of Orelabrutinib Combined With Rituximab Versus Lenalidomide Combined With Rituximab in Patients With Relapsed/Refractory Marginal Zone Lymphoma正在招募NCT06082102研究中心III期2023-12 启动
  10. A Study of BGB-16673 Compared to Investigator's Choice in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Covalent Bruton Tyrosine Kinase (BTK) Inhibitors进行中,不再招募NCT06970743研究中心III期2025-05 启动
  11. A Study of Rocbrutinib in Participants With Relapse or Refractory Mantle Cell Lymphoma进行中,不再招募NCT05716087研究中心II期2023-02 启动
  12. A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)进行中,不再招募NCT04965493研究中心III期2021-09 启动
  13. Clinical Study of HMPL-689 for Relapsed/Refractory Marginal Zone Lymphoma and Follicular Lymphoma已完成NCT04849351研究中心II期2021-04 启动
  14. A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.进行中,不再招募NCT04224493研究中心III期2020-06 启动
  15. A Study of TQ-B3525 in the Treatment of Relapsed / Refractory Follicular Lymphoma (FL)状态不明NCT04324879研究中心II期2020-05 启动
  16. A Study to Evaluate ICP-022 in Patients With R/R Marginal Zone Lymphoma (MZL)已完成NCT03797456研究中心II期2019-04 启动
  17. Study of TQB2450 Injection in Subjects With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma已终止NCT04002622研究中心II期2019-08 启动
  18. A Study to Evaluate ICP-022 in Patients With R/R Mantle Cell Lymphoma (MCL)已完成NCT03494179研究中心I/II期2018-04 启动

打开 PubMed 检索ClinicalTrials.gov

血液疾病

血友病 A

Haemophilia A

2021–2025 年中国大陆作者发表的 272 篇血友病 A PubMed 英文论文中,这家医院牵头了 2 篇,占 0.7%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 1120232024: 0020242025: 112025

郑州有 5 家医院列在血友病 A下全国有 132 家医院列在血友病 A下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的血友病 A开放试验。

这些数字背后的记录
论文中的科室影像/核医学科普外/肝胆胰外科
牵头的论文2
  1. The prediction of haemophilic arthropathy progression based on MRI findings and clinical characteristics.2025Orphanet journal of rare diseases免费全文
  2. Acquired Hemophilia A: A Retrospective Multicenter Analysis of 42 Patients.2023Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis免费全文
早期论文(2016–2020 年)4
  1. Multislice spiral computed tomography imaging in evaluating hemophilic arthropathy.2020Chinese medical journal
  2. [Clinical study on factor Ⅷ inhibitor in children with hemophilia A].2020Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
  3. Using synovial volume measurement by MRI to evaluate the effect of 32P Radiation synovectomy on hemophilic arthropathy patients.2019Journal of X-ray science and technology
  4. [Therapeutic response of radiosynovectomy with p-32 colloid in 326 patients with hemophilic arthropathy].2017Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
它在 ClinicalTrials.gov 上的全部试验(任何状态)7
  1. Phase 3 Clinical Project of Pegylated Recombinant Human Coagulation Factor VIII-Fc Fusion Protein已完成NCT06142552研究中心III期2023-12 启动
  2. Clinical Study of Recombinant Human Activated Coagulation Factor VII for Injection in Patients With Hemophilia With Inhibitor状态不明NCT05487976研究中心III期2022-04 启动
  3. Phase III Expansion Trial for Determining the Safety and Efficacy of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection in Adolescent and Adult Patients With Hemophilia A已完成NCT04845399研究中心III期2021-04 启动
  4. An Open Label Study to Determine the Safety and Efficacy of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection in Adolescent and Adult Patients With Hemophilia A.已完成NCT04456387研究中心III期2020-10 启动
  5. Safety, Efficacy Evaluation of Recombinant Coagulation Factor VIII Injection in Subjects With Hemophilia A.状态不明NCT04061109研究中心III期2019-05 启动
  6. PF-05208756, Moroctocog Alfa (AF-CC), Xyntha For Hemophilia A已完成NCT02492984研究中心IV期2015-04 启动
  7. Retrospective Chart Review to Evaluate Safety and Tolerability of ADVATE Among Previously Untreated Patients in China With Moderate to Severe Hemophilia A已完成NCT02634723研究中心2015-12 启动

打开 PubMed 检索ClinicalTrials.gov

血液疾病

血栓性血小板减少性紫癜

Thrombotic thrombocytopenic purpura

2021–2025 年中国大陆作者发表的 64 篇血栓性血小板减少性紫癜 PubMed 英文论文中,这家医院牵头了 1 篇,占 1.6%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025

郑州有 2 家医院列在血栓性血小板减少性紫癜下全国有 59 家医院列在血栓性血小板减少性紫癜下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的血栓性血小板减少性紫癜开放试验。

这些数字背后的记录
论文中的科室神经内科

打开 PubMed 检索ClinicalTrials.gov

血液疾病

范可尼贫血

Fanconi anaemia

2021–2025 年中国大陆作者发表的 68 篇范可尼贫血 PubMed 英文论文中,这家医院牵头了 1 篇,占 1.5%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

郑州有 2 家医院列在范可尼贫血下全国有 40 家医院列在范可尼贫血下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的范可尼贫血开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他疾病

视神经脊髓炎谱系疾病

Neuromyelitis optica spectrum disorder

2021–2025 年中国大陆作者发表的 485 篇视神经脊髓炎谱系疾病 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.4%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 0020222023: 0020232024: 1120242025: 002025

郑州有 2 家医院列在视神经脊髓炎谱系疾病下全国有 67 家医院列在视神经脊髓炎谱系疾病下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    A Clinical Study of B001 Injection in the Treatment of Neuromyelitis Optica Spectrum Disorders(NMOSD)
    分期
    II/III期
    开始
    2024-07
    发布
    登记号
    NCT06413654

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 27 家列出的医院为研究中心北京、厦门、合肥、哈尔滨、天津、太原、广州、成都、昆明、杭州、武汉、沈阳、济南、温州、石家庄、福州、郑州、长沙

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题抗体与诊断
论文中的科室神经内科
牵头的论文2
  1. Single-cell RNA sequencing reveals cell type-specific immune regulation associated with human neuromyelitis optica spectrum disorder.2024Frontiers in immunology免费全文
  2. Watch out for neuromyelitis optica spectrum disorder after inactivated virus vaccination for COVID-19.2021Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. A Clinical Study of B001 Injection in the Treatment of Neuromyelitis Optica Spectrum Disorders(NMOSD)正在招募NCT06413654研究中心II/III期2024-07 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

重症肌无力

Myasthenia gravis

2021–2025 年中国大陆作者发表的 499 篇重症肌无力 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.4%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 1120242025: 112025

郑州有 3 家医院列在重症肌无力下全国有 89 家医院列在重症肌无力下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)
    分期
    III期
    开始
    2024-06
    发布
    登记号
    NCT06463587

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 14 家列出的医院为研究中心上海、北京、广州、成都、武汉、沈阳、石家庄、蚌埠、遵义、郑州、长春、长沙

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题生物制剂与补体抑制剂常规免疫治疗
论文中的科室神经内科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

烟雾病

Moyamoya disease

2021–2025 年中国大陆作者发表的 356 篇烟雾病 PubMed 英文论文中,这家医院牵头了 5 篇,占 1.4%。

牵头论文
5
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 3320222023: 0020232024: 0020242025: 222025

郑州有 2 家医院列在烟雾病下全国有 47 家医院列在烟雾病下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Development and Validation of Risk Prediction Models for Stroke and Cognitive Impairment in Moyamoya Disease and Moyamoya Syndrome
    分期
    未注明
    开始
    2026-08
    发布
    登记号
    NCT07894107

    年龄 12 岁 至 70 岁(登记的条件)

    牵头:首都医科大学附属北京天坛医院;另有 12 家列出的医院为研究中心上海、北京、南昌、成都、杭州、武汉、苏州、郑州

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题遗传血管重建手术影像与脑血流
论文中的科室神经外科神经内科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

冠心病

Coronary heart disease

2021–2025 年中国大陆作者发表的 5,119 篇冠心病 PubMed 英文论文中,这家医院牵头了 26 篇,占 0.5%。

牵头论文
26
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 5520212022: 5520222023: 7720232024: 3320242025: 662025

郑州有 6 家医院列在冠心病下全国有 231 家医院列在冠心病下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月18日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 即将招募
    Optimized Antiplatelet Therapy in Patients With CHD After Implantation of NeoVas™ BRS System
    分期
    不分期
    开始
    2021-09
    发布
    登记号
    NCT04995159

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 67 家列出的医院为研究中心上海、中山、兰州、北京、南京、南宁、南昌、合肥、哈尔滨、天津、太原、广州、徐州、昆明、杭州、武汉、汕头、洛阳、济南、海口、淄博、淮安、湛江、烟台、珠海、石家庄、蚌埠、西安、贵阳、郑州、重庆、银川、长春、长沙、青岛

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
论文中的科室影像/核医学科病理/检验科风湿免疫科
牵头的论文26
  1. Carotid intima thickness and elasticity combined with MHR predicting the severity of coronary artery stenosis in patients with premature coronary artery disease.2025BMC cardiovascular disorders免费全文
  2. Impact of Insomnia on Myocardial Infarction Risk and Coronary Plaque Vulnerability: Insights From Mendelian Randomization and OCT Imaging.2025Clinical cardiology免费全文
  3. Serum sST2, IL-33, and Hcy Expression in Older Adults Patients with Myocardial Infarction and Their Predictive Value for MACE.2025Clinical interventions in aging免费全文
  4. Elevated serum uric acid as an independent risk factor for multiple stent placement in non-hypertensive, non-diabetic patients with coronary artery disease: a retrospective cohort analysis.2025Clinical rheumatology
  5. Unveiling the role of risk factors and predictive models in acute type-a aortic dissection surgery: OI downregulation and its association with immune disorders.2025International journal of medical sciences免费全文
  6. Relationship Between Aldehyde Dehydrogenase 2 Gene Polymorphism and Vasodilative Effect of Nitroglycerin on Coronary Arteries.2025Journal of cardiovascular pharmacology
  7. Insulin resistance and coronary inflammation in patients with coronary artery disease: a cross-sectional study.2024Cardiovascular diabetology免费全文
  8. Diagnostic and prognostic value of serum Cys-C, retinol-binding protein, and ischemia-modified albumin in patients with coronary heart disease: A diagnostic accuracy study.2024Medicine免费全文
  9. Optical coherence tomography analysis of lesion characteristics and thrombus types in non ST-segment elevation myocardial infarction patients.2024The international journal of cardiovascular imaging免费全文
  10. Kinesiophobia and its associated factors in patients with coronary heart disease: a cross-sectional study based on latent feature analysis.2023BMJ open免费全文
  11. Triglyceride-glucose index as a marker of adverse cardiovascular prognosis in patients with coronary heart disease and hypertension.2023Cardiovascular diabetology免费全文
  12. Safety and efficacy of enterprise stenting for symptomatic atherosclerotic severe posterior circulation stenosis.2023European journal of medical research免费全文
  13. Validation of a predictive model for coronary artery disease in patients with diabetes.2023Journal of cardiovascular medicine (Hagerstown, Md.)免费全文
  14. Clinical characteristics and outcomes of Chinese patients with coronary heart disease and resistant hypertension.2023Journal of clinical hypertension (Greenwich, Conn.)免费全文
  15. The "L-Sandwich" Strategy for True Coronary Bifurcation Lesions: A Randomized Clinical Trial.2023Journal of interventional cardiologyRCT免费全文
  16. SPECT myocardial blood flow quantitation for the detection of angiographic stenoses with cardiac-dedicated CZT SPECT.2023Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology
  17. GAS5/METTL14/ESR1 genetic variants are related to the susceptibility of coronary heart disease.2022Functional & integrative genomics
  18. Remote ischemic preconditioning can extend the tolerance to extended drug-coated balloon inflation time by reducing myocardial damage during percutaneous coronary intervention.2022International journal of cardiologyRCT
  19. Clinical and imaging characteristics of cardiac magnetic resonance presenting with myocardial infarction with non-obstructive coronary arteries in China.2022Journal of cardiothoracic surgery免费全文
  20. Histone Deacetylase 1 Depletion Alleviates Coronary Heart Disease Via the MicroRNA-182-Mediated Transforming Growth Factor β/Smad Signaling Pathway.2022Journal of cardiovascular pharmacology
  21. Relationship between cognitive emotion regulation strategies and coronary heart disease: an empirical examination of heart rate variability and coronary stenosis.2022Psychology & health
  22. Prediction of all-cause mortality in coronary artery disease patients with atrial fibrillation based on machine learning models.2021BMC cardiovascular disorders免费全文
  23. Lipid profile and prognosis in patients with coronary heart disease: a meta-analysis of prospective cohort studies.2021BMC cardiovascular disorders免费全文
  24. Suppression of microRNA-323-3p restrains vascular endothelial cell apoptosis via promoting sirtuin-1 expression in coronary heart disease.2021Life sciences
  25. Analysis of Characteristics of Patients with Non-ST-Segment Elevation Myocardial Infarction by Cardiac Magnetic Resonance Imaging.2021Medical science monitor : international medical journal of experimental and clinical research免费全文
  26. Factors affecting in-stent restenosis after angioplasty with the Enterprise stent for intracranial atherosclerotic diseases.2021Scientific reports免费全文
中文论文(未计入)3
  1. [The relationship between variant angina pectoris syncope and coronary artery spastic targeted location, arrhythmia and coronary artery stenostic lesion].2025Zhonghua xin xue guan bing za zhi
  2. [Clinical efficacy evaluation of minimally invasive cardiac surgery coronary artery bypass grafting in patients with multivessel coronary artery disease].2022Zhonghua yi xue za zhi
  3. [Association of RAGE gene polymorphisms with MHR ratio and heart rate variability among patients with coronary heart disease].2021Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics
它在 ClinicalTrials.gov 上的全部试验(任何状态)4
  1. Optimized Antiplatelet Therapy in Patients With CHD After Implantation of NeoVas™ BRS System即将招募NCT04995159研究中心不分期2021-09 启动
  2. Effect of Antithrombotic Treatment in Patients With Both Coronary Heart Disease and Atrial Fibrillation状态不明NCT03051061研究中心2017-02 启动
  3. Atorvastatin Effectiveness and Safety in Cardiology Patients in Real World Setting已完成NCT02565615研究中心2016-06 启动
  4. Efficacy and Safety of the YUKON Drug Eluting Stent in Diffuse Coronary Artery Disease状态不明NCT01418794研究中心IV期2010-10 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

先天性心脏病

Congenital heart disease

2021–2025 年中国大陆作者发表的 2,604 篇先天性心脏病 PubMed 英文论文中,这家医院牵头了 14 篇,占 0.5%。

牵头论文
14
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 3320212022: 2220222023: 4420232024: 2220242025: 222025

郑州有 6 家医院列在先天性心脏病下全国有 207 家医院列在先天性心脏病下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月18日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 即将招募
    A Multicenter Study on the Normal Reference Range and Clinical Significance of the Right Atrioventricular Coupling Index Assessed by Artificial Intelligence-Based Three-Dimensional Echocardiography
    分期
    未注明
    开始
    2025-12
    发布
    登记号
    NCT07292896

    年龄 18 岁 至 79 岁(登记的条件)

    牵头:中国医科大学附属第一医院;另有 11 家列出的医院为研究中心上海、北京、太原、成都、武汉、沈阳、深圳、西安、郑州、长春、青岛

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
论文中的科室影像/核医学科
牵头的论文14
  1. Identification of novel biallelic mutations in CFAP53 associated with fetal situs inversus totalis and literature review.2026Journal of applied genetics
  2. Remimazolam for successful sedation in children with left-to-right shunt congenital heart disease: An up-and-down sequential allocation trial.2025European journal of anaesthesiology免费全文
  3. Unveiling the role of risk factors and predictive models in acute type-a aortic dissection surgery: OI downregulation and its association with immune disorders.2025International journal of medical sciences免费全文
  4. Impacts of gene variants on drug effects-the foundation of genotype-guided pharmacologic therapy for long QT syndrome and short QT syndrome.2024EBioMedicine免费全文
  5. Identifying the critical windows of temperature extremes exposure and congenital heart diseases.2024International journal of biometeorology
  6. Alternating Early Afterdepolarizations Underlying Bradycardia-Dependent Macroscopic T Wave and Discordant Mechanical Alternans.2023Circulation. Arrhythmia and electrophysiology
  7. Trans-jugular transcutaneous closure of atrial septal defects with an adjustable curved sheath under echocardiography guidance.2023Echocardiography (Mount Kisco, N.Y.)
  8. Peratrial device closure of perimembranous ventricular septal defects via a small right subaxillary incision: Midterm results in patients <12 months of age.2023International journal of cardiology
  9. A novel mutation in PCD-associated gene DNAAF3 causes male infertility due to asthenozoospermia.2023Journal of cellular and molecular medicine免费全文
  10. Preoperative sedation in children with congenital heart disease: 50% and 95% effective doses, hemodynamic effects, and safety of intranasal dexmedetomidine.2022Journal of clinical anesthesia
  11. Different effects of maternal homocysteine concentration, MTHFR and MTRR genetic polymorphisms on the occurrence of fetal aneuploidy.2022Reproductive biomedicine online
  12. Exploration and validation of hub genes and pathways in the progression of hypoplastic left heart syndrome via weighted gene co-expression network analysis.2021BMC cardiovascular disorders免费全文
  13. Knockdown of Long Noncoding RNA SNHG14 Protects H9c2 Cells Against Hypoxia-induced Injury by Modulating miR-25-3p/KLF4 Axis in Vitro.2021Journal of cardiovascular pharmacology
  14. Asymmetric Occluder Occlusion of Outlet Ventricular Septal Defect Via a Subaxillary Approach.2021The Annals of thoracic surgery
中文论文(未计入)3
  1. [Genetic analysis of primary ciliary dyskinesia caused by DNAH5 splicing site mutations].2025Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases
  2. [Early warning of low maternal unconjugated estriol level by prenatal screening for fetus with X-linked ichthyosis].2022Zhonghua fu chan ke za zhi
  3. [Effect and prognosis of new type of re-dilated stent in the treatment of pulmonary artery bifurcation stenosis].2022Zhonghua yi xue za zhi
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. A Multicenter Study on the Normal Reference Range and Clinical Significance of the Right Atrioventricular Coupling Index Assessed by Artificial Intelligence-Based Three-Dimensional Echocardiography即将招募NCT07292896研究中心2025-12 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

脊柱侧弯

Scoliosis

2021–2025 年没有牵头脊柱侧弯的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头

郑州有 2 家医院列在脊柱侧弯下全国有 107 家医院列在脊柱侧弯下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月18日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Tegileridine for Postoperative Pain After Adolescent Scoliosis Surgery
    分期
    IV期
    开始
    2026-04
    发布
    登记号
    NCT07229495

    年龄 10 岁 至 17 岁(登记的条件)

    牵头:北京协和医院;另有 5 家列出的医院为研究中心上海、北京、南昌、郑州

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
它在 ClinicalTrials.gov 上的全部试验(任何状态)2
  1. Tegileridine for Postoperative Pain After Adolescent Scoliosis Surgery正在招募NCT07229495研究中心IV期2026-04 启动
  2. Degenerative Lumbar Scoliosis状态不明NCT05485636研究中心2022-08 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

抗 NMDA 受体脑炎

Anti-NMDA receptor encephalitis

2021–2025 年中国大陆作者发表的 264 篇抗 NMDA 受体脑炎 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.8%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 1120222023: 0020232024: 0020242025: 002025

郑州有 6 家医院列在抗 NMDA 受体脑炎下全国有 124 家医院列在抗 NMDA 受体脑炎下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的抗 NMDA 受体脑炎开放试验。

这些数字背后的记录
论文中的科室神经内科
牵头的论文2
  1. Single-cell transcriptomics reveals cell type-specific immune regulation associated with anti-NMDA receptor encephalitis in humans.2022Frontiers in immunology免费全文
  2. Autoimmune-mediated secondary-parkinsonism presented with micrographia and cognitive impairment.2021Journal of neuroimmunology
早期论文(2016–2020 年)2
  1. Elevated CHI3L1 and OPN levels in patients with anti-N-methyl-d-aspartate receptor encephalitis.2019Journal of neuroimmunology
  2. Anti-N-methyl-D-aspartate receptor encephalitis with lung adenocarcinoma.2016Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology

打开 PubMed 检索ClinicalTrials.gov

其他疾病

大动脉炎

Takayasu arteritis

2021–2025 年没有牵头大动脉炎的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

郑州有 2 家医院列在大动脉炎下全国有 100 家医院列在大动脉炎下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的大动脉炎开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他疾病

特发性肺纤维化

Idiopathic pulmonary fibrosis

2021–2025 年中国大陆作者发表的 989 篇特发性肺纤维化 PubMed 英文论文中,这家医院牵头了 5 篇,占 0.5%。

牵头论文
5
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
2
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 1120232024: 0020242025: 332025

郑州有 8 家医院列在特发性肺纤维化下全国有 288 家医院列在特发性肺纤维化下

这家医院参与的开放试验 2

依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Study Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF)
    分期
    III期
    开始
    2026-09
    发布
    登记号
    NCT07687459

    年龄 40 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 45 家列出的医院为研究中心上海、乌鲁木齐、北京、南京、南宁、南昌、南阳、厦门、合肥、呼和浩特、天津、太原、宁波、宜昌、广州、徐州、成都、昆明、杭州、武汉、沈阳、济南、海口、温州、石家庄、福州、西安、运城、郑州、长春、长沙

  2. 正在招募
    A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of SV001 in Patients With Idiopathic Pulmonary Fibrosis
    分期
    II期
    开始
    2025-11
    发布
    登记号
    NCT07121413

    年龄 40 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 12 家列出的医院为研究中心上海、南京、南昌、呼和浩特、天津、广州、徐州、成都、杭州、郑州

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
牵头的论文5
  1. Antidepressant intervention to possibly delay disease progression and frailty in elderly idiopathic pulmonary fibrosis patients: a clinical trial.2025Aging clinical and experimental research免费全文
  2. Potential function exploration of lncRNAs in idiopathic pulmonary fibrosis: insights from whole transcriptome sequencing data analysis.2025Clinics (Sao Paulo, Brazil)免费全文
  3. Integrative Analysis of Endothelial Cell Senescence-Related Genes in Idiopathic Pulmonary Fibrosis.2025FASEB journal : official publication of the Federation of American Societies for Experimental Biology
  4. Genetic association of telomere length, obesity and tobacoo smoking with idiopathic pulmonary fibrosis risk.2023BMC public health免费全文
  5. Contribution of Adiponectin/Carnitine Palmityl Transferase 1A-Mediated Fatty Acid Metabolism during the Development of Idiopathic Pulmonary Fibrosis.2022Oxidative medicine and cellular longevity免费全文
早期论文(2016–2020 年)3
  1. Research Advances on DNA Methylation in Idiopathic Pulmonary Fibrosis.2020Advances in experimental medicine and biology
  2. Downregulation of microRNA‑30a in bronchoalveolar lavage fluid from idiopathic pulmonary fibrosis patients.2018Molecular medicine reports
  3. Gastroesophageal Reflux Disease in Idiopathic Pulmonary Fibrosis: Uncertainties and Controversies.2018Respiration; international review of thoracic diseases
它在 ClinicalTrials.gov 上的全部试验(任何状态)5
  1. Study Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF)正在招募NCT07687459研究中心III期2026-09 启动
  2. A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of SV001 in Patients With Idiopathic Pulmonary Fibrosis正在招募NCT07121413研究中心II期2025-11 启动
  3. Menstrual Blood-Derived Mesenchymal Stem Cell Injection (SC01009) in the Treatment of Idiopathic Pulmonary Fibrosis即将招募NCT07131150研究中心II期2025-08 启动
  4. Randomized, Double-blind Study of Efficacy and Safety of Bexotegrast (PLN-74809) for Idiopathic Pulmonary Fibrosis已终止NCT06097260研究中心II期2023-11 启动
  5. Zephyrus I: Evaluation of Efficacy and Safety of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)已终止NCT03955146研究中心III期2019-06 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

肌萎缩侧索硬化症

Amyotrophic lateral sclerosis

2021–2025 年中国大陆作者发表的 779 篇肌萎缩侧索硬化症 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.1%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

郑州有 3 家医院列在肌萎缩侧索硬化症下全国有 182 家医院列在肌萎缩侧索硬化症下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的肌萎缩侧索硬化症开放试验。

这些数字背后的记录
论文中的科室神经内科
牵头的论文1
  1. Two new cases with the UBQLN2 gene mutation in Han Chinese.2024Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
早期论文(2016–2020 年)2
  1. Novel mutation in optineurin causing aggressive ALS+/-frontotemporal dementia.2019Annals of clinical and translational neurology
  2. A novel SETX gene mutation associated with Juvenile amyotrophic lateral sclerosis.2018Brain and behavior

打开 PubMed 检索ClinicalTrials.gov

其他疾病

杜氏肌营养不良

Duchenne muscular dystrophy

2021–2025 年中国大陆作者发表的 213 篇杜氏肌营养不良 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.5%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

郑州有 5 家医院列在杜氏肌营养不良下全国有 111 家医院列在杜氏肌营养不良下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的杜氏肌营养不良开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他疾病

IgA 肾病

IgA nephropathy

2021–2025 年中国大陆作者发表的 736 篇IgA 肾病 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.1%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

郑州有 3 家医院列在IgA 肾病下全国有 300 家医院列在IgA 肾病下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的IgA 肾病开放试验。

这些数字背后的记录
论文中的科室肾内科
牵头的论文1
  1. Molecular Pathogenic Mechanisms of IgA Nephropathy Secondary to COVID-19 mRNA Vaccination.2024Kidney & blood pressure research
它在 ClinicalTrials.gov 上的全部试验(任何状态)4
  1. A Study of SGB-9768 in Patients With Complement-mediated Kidney Diseases进行中,不再招募NCT06786338研究中心II期2025-06 启动
  2. A Study of Telitacicept for IgA Nephropathy (TELIGAN)进行中,不再招募NCT05799287研究中心III期2023-04 启动
  3. Efficacy and Safety of Abelmoschus Manihot for IgA Nephropathy状态不明NCT02231125研究中心IV期2014-09 启动
  4. Therapeutic Evaluation of Steroids in IgA Nephropathy Global Study (TESTING Low Dose Study)已完成NCT01560052研究中心不分期2012-05 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

成骨不全症

Osteogenesis imperfecta

2021–2025 年没有牵头成骨不全症的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

郑州有 3 家医院列在成骨不全症下全国有 58 家医院列在成骨不全症下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的成骨不全症开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他疾病

原发性胆汁性胆管炎

Primary biliary cholangitis

2021–2025 年没有牵头原发性胆汁性胆管炎的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
3
由其他机构牵头

郑州有 2 家医院列在原发性胆汁性胆管炎下全国有 153 家医院列在原发性胆汁性胆管炎下

这家医院参与的开放试验 3

依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    A Study of CS0159 in Patients With PBC With Inadequate Response or Intolerance to UDCA
    分期
    III期
    开始
    2025-12
    发布
    登记号
    NCT07282353

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 35 家列出的医院为研究中心上海、临沂、北京、十堰、南京、南宁、南昌、厦门、台州、合肥、哈尔滨、天津、宝鸡、成都、杭州、沈阳、深圳、湛江、福州、西安、郑州、重庆、长春、长沙、青岛

  2. 正在招募
    Fenofibrate for Compensated Cirrhosis Patients With Primary Biliary Cholangitis
    分期
    II/III期
    开始
    2023-02
    发布
    登记号
    NCT05749822

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:空军军医大学西京医院;另有 11 家列出的医院为研究中心北京、南京、天津、广州、延安、成都、昆明、沈阳、西安、郑州、长沙

  3. 正在招募
    Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis
    分期
    III期
    开始
    2023-09
    发布
    登记号
    NCT06051617

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 17 家列出的医院为研究中心上海、乌鲁木齐、北京、合肥、广州、成都、杭州、武汉、福州、西安、贵阳、郑州、重庆、长春

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
它在 ClinicalTrials.gov 上的全部试验(任何状态)4
  1. A Study of CS0159 in Patients With PBC With Inadequate Response or Intolerance to UDCA正在招募NCT07282353研究中心III期2025-12 启动
  2. Fenofibrate for Compensated Cirrhosis Patients With Primary Biliary Cholangitis正在招募NCT05749822研究中心II/III期2023-02 启动
  3. Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis正在招募NCT06051617研究中心III期2023-09 启动
  4. CS0159 in Chinese Patients With PBC (Primary Biliary Cholangitis)进行中,不再招募NCT05896124研究中心II期2023-08 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

原发性硬化性胆管炎

Primary sclerosing cholangitis

2021–2025 年没有牵头原发性硬化性胆管炎的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头

郑州有 1 家医院列在原发性硬化性胆管炎下全国有 89 家医院列在原发性硬化性胆管炎下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    A Study to Assess How Well and Safely Elafibranor Works in Adult Participants With Primary Sclerosing Cholangitis
    分期
    III期
    开始
    2026-05
    发布
    登记号
    NCT07387549

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 11 家列出的医院为研究中心上海、北京、南昌、天津、广州、济南、郑州、长春

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. A Study to Assess How Well and Safely Elafibranor Works in Adult Participants With Primary Sclerosing Cholangitis正在招募NCT07387549研究中心III期2026-05 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

遗传性大疱性表皮松解症

Inherited epidermolysis bullosa

2021–2025 年中国大陆作者发表的 56 篇遗传性大疱性表皮松解症 PubMed 英文论文中,这家医院牵头了 2 篇,占 3.6%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 2220232024: 0020242025: 002025

郑州有 3 家医院列在遗传性大疱性表皮松解症下全国有 41 家医院列在遗传性大疱性表皮松解症下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的遗传性大疱性表皮松解症开放试验。

这些数字背后的记录
牵头的论文2
  1. Dystrophic Epidermolysis Bullosa Pruriginosa: Successfully Treated With Dupilumab.2023Dermatitis : contact, atopic, occupational, drug
  2. Haplotype-based non-invasive prenatal diagnosis of recessive dystrophic epidermolysis bullosa via targeted capture sequencing of maternal plasma.2023The Journal of dermatology
中文论文(未计入)1
  1. [Variation of COL7A1 gene in dystrophic epidermolysis bullosa pruriginosa].2022Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics
早期论文(2016–2020 年)1
  1. [Genetic analysis of a child with recessive dystrophic epidermolysis bullosa due to compound heterozygous variants of (COL7A1 gene].2020Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics

打开 PubMed 检索ClinicalTrials.gov

其他疾病

遗传性血管性水肿

Hereditary angioedema

2021–2025 年没有牵头遗传性血管性水肿的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

郑州有 1 家医院列在遗传性血管性水肿下全国有 30 家医院列在遗传性血管性水肿下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的遗传性血管性水肿开放试验。

这些数字背后的记录
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. A Study of Lanadelumab (Takhzyro) and Icatibant (Firazyr®) in Persons With HAE in China已完成NCT06346899研究中心2024-07 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

Leber 遗传性视神经病变

Leber hereditary optic neuropathy

2021–2025 年中国大陆作者发表的 52 篇Leber 遗传性视神经病变 PubMed 英文论文中,这家医院牵头了 3 篇,占 5.8%。

牵头论文
3
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 1120222023: 1120232024: 0020242025: 002025

郑州有 2 家医院列在Leber 遗传性视神经病变下全国有 30 家医院列在Leber 遗传性视神经病变下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的Leber 遗传性视神经病变开放试验。

这些数字背后的记录
论文中的科室影像/核医学科

打开 PubMed 检索ClinicalTrials.gov

联系这家医院

出示给工作人员或司机的院名卡

河南省人民医院

Henan Provincial People's Hospital

郑州

大医院往往有多个院区,出发前请先向医院确认院区。

中英对照的咨询信

填写方括号中的内容后,通过医院国际医疗部或官网上的联系方式发送。在这里输入的内容不会离开您的设备。

医院通常需要的资料

  • 主治医生近期的病情总结或信件
  • 病理报告
  • 影像检查(CT、MRI、PET)及报告,尽量附影像文件
  • 已接受的治疗及时间
  • 目前用药

下一步建议

与主治医生沟通可将本页分享给主治医生,一同评估该团队的研究方向是否相关。
确认团队现状论文发表通常滞后数月,医生也可能调动。请在医院官网查询相关科室。
直接联系医院请通过医院官方公布的渠道联系。医院不向我们支付任何费用;是否接诊由医院决定。

这些数字从哪里来

论文

2021–2025 年 PubMed 英文论文中,第一作者或最后作者的第一单位是这家医院的论文。 定义

试验

ClinicalTrials.gov 上列出这家医院为牵头方或研究中心的记录,截至 2026年11月8日。

编号与其他名称

ROR Wikidata
People's Hospital of Zhengzhou University; Zhengzhou University People's Hospital; and Affiliated Provincial People's Hospital of Zhengzhou University; Heart Center of Henan Provincial People's Hospital; Henan Provincial People' Hospital; Affiliated People's Hospital of Zhengzhou University; Henan Provincial People's Hospital Affiliated to Zhengzhou University; and Henan Provincial People's Hospital

提出更正下载数据